



US 20110281850A1

(19) **United States**

(12) **Patent Application Publication**
Flynn et al.

(10) **Pub. No.: US 2011/0281850 A1**

(43) **Pub. Date: Nov. 17, 2011**

(54) **INTRACELLULAR KINASE INHIBITORS**

Publication Classification

(75) Inventors: **Gary A. Flynn**, Tucson, AZ (US);
Sandra Aeyoung Lee, Sherman
Oaks, CA (US); **Mary Faris**, Los
Angeles, CA (US); **David William**
Brandt, Moorpark, CA (US);
Subrata Chakravarty, Valencia,
CA (US)

(51) **Int. Cl.**
A61K 31/551 (2006.01)
A61K 31/437 (2006.01)
A61K 31/5377 (2006.01)
A61K 31/137 (2006.01)
A61P 7/00 (2006.01)
A61K 31/472 (2006.01)
A61K 31/5375 (2006.01)
A61K 31/538 (2006.01)
A61K 31/54 (2006.01)
A61P 35/02 (2006.01)
A61K 31/4453 (2006.01)
A61K 31/495 (2006.01)

(73) Assignee: **MANKIND CORPORATION**,
Valencia, CA (US)

(21) Appl. No.: **13/177,657**

(22) Filed: **Jul. 7, 2011**

(52) **U.S. Cl. 514/218**; 514/319; 514/300; 514/235.5;
514/657; 514/255.03; 514/252.12; 514/307;
514/238.8; 514/230.5; 514/231.8; 514/227.5

Related U.S. Application Data

(63) Continuation of application No. 11/750,866, filed on
May 18, 2007.

(60) Provisional application No. 60/869,664, filed on Dec.
12, 2006, provisional application No. 60/801,074,
filed on May 18, 2006.

(57) **ABSTRACT**

Intracellular kinase inhibitors and their therapeutic uses for
patients with T cell malignancies, B cell malignancies,
autoimmune disorders, and transplanted organs.




FIG. 1

FIG. 2

huITK	5	ILLEEQLIKKSQQKRRTSPSNFKVRFVLTAKASLAYFED--RHGKKRTLKGSIELSRIKC	62
		++LE +K+SQQK++TSP NFK R F+LT L+Y+E G++ + KGSII++ +I C	
huBTK	4	VILESIFLKRSSQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRGSKKGSIDVEKITC	63
Query	63	VEIVKSD-----ISIPCHYKYPFQVVHDNYLLYVTFAPDRESRQR	101
		VE V + ISI + YPFQVV+D LYVF+P E R+R	
Sbjct	64	VETVVPKPNPPERQIPRRGEESEMEEQISIIERFPYPFQVVYDEGPLYVFSPTTEELRKR	123
Query	102	WVLALKEETRNNNSLVPKYHPNFWMDGKWRCCSQLEKLATGCAQYDPTKNAS-----	153
		W+ LK R N+ LV KYHP FW+DG++ CCSQ K A GC Q +N S	
Sbjct	124	WIHQLNKVNIRYNSDLVQYHPCFWIDGQYLCCSQTAKNAMGC-QILENRNGSLKPGSSHR	182
Query	154	--KKPLPPTPEDNR-----RPLWEPEETVVIALYDYQTNDPQELALRRNEEYC	199
		KKPLPPTPE+++ P+ E V+ALYDY + +L LR+ +EY	
Sbjct	183	KTKKPLPPTPEEDQILKKPLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQLRKGDEYF	242
Query	200	LLDSSEIHWWRVQDRNGHEGYVPSSYLVEKSPNNLETYEWYNKISIRDKAEKLLLDTCKE	259
		+L+ S + WWR +D+NG EGY+PS+Y+ E + +++E YEWY+K ++R +AE+LL GKE	
Sbjct	243	ILEESNLPWWRARDKNGQEGYIPSNYVTE-AEDSIEMYEWYSKHMTRSQAELQLKQEGKE	301
Query	260	GAFMVRDSRTAGTYTVSVFTKAVVSENNPCIKHYHIKETNDNPKRYYVAEKYVFDSDIPLL	319
		G F+VRDS AG YTVSVF K+ I I+HY I T I +YY+AEK+IF +IP L	
Sbjct	302	GGFIVRDSKAGKYTVSVFAKST-GDPQGVIRHYVVCSTPQS--QYYLAEKHLFSTIPEL	358
Query	320	INYHQHNGGGLVTRLRYPVCFCGRQKAPVTAGLRYGKWVIDPSELTFVQEIGSGQFGLVHL	379
		INYHQHN GL++RL+YPV + AP TAGL YG W IDP +LTF++E+G+GQFG+V	
Sbjct	359	INYHQHNSAGLISRLKYPVSQQNKNAPOSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKY	418
Query	380	GYWLNKDKVAIKTIREGAMSEEDFIEEAEVMMKLSHPKLVQLYGVCLEQAPICLVFEFME	439
		G W + VAIK I+EG+MSE++FIEEA+VMM LSH KLVQLYGVC +Q PI ++ E+M	
Sbjct	419	GKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMA	478
huITK	440	HGCLSDYLRTQRGLFAAETLLGMCLDVCEGMAYLEEACVIHRDLAARNCLVGENQVIKVS	499
		+GCL +YLR R F + LL MC DVCE M YLE +HRDLAARNCLV + V+KVS	
huBTK	479	NGCLLNLYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVS	538
Query	500	DFGMTRFVLDQYTSSTGTFKFPVKWASPEVFSFSRYSSKSDVWSFGVLMWEVFESEKIPY	559
		DFG++R+VLDD+YTSS G+K'PV+W+ PEV +S++SSKSD+W+FGVLMWE++S GK+PY	
Sbjct	539	DFGLSRYVLDDEYTSSVGSKFPVRSPEVLMYSKFSKSDIWFAGVLMWEIYSLGKMPY	598
Query	560	ENRNSNEVVEDISTGFRLYKPRLASTHVYQIMNHCWKERPDRPAFSRLLRQLAEIAE	617
		E +NSE E I+ G RLY+P LAS VY IM CW E+ ++RP F LL + ++ +	
Sbjct	599	ERFTNSETAEHIAOGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMD	656

FIG. 3

TK_Tec__BTK	LTFLKELGTGQFGVVKYGKWRG-----QYDVAIKMIKEGS (SEQ ID NO:3)
TK_Tec__BMX	ITLLKELGSGQFGVVQLGKWKG-----QYDVAVKMIKEGS (SEQ ID NO:4)
TK_Tec__TEC	LTFMRELGSGLFGVVRLGKWRA-----QYKVAIKAIREGA (SEQ ID NO:5)
TK_Tec__TXK	LAFIKBIGSGQFGVVHLGEWRS-----HIQVAIKAINEGS (SEQ ID NO:6)
TK_Tec__ITK	LTFVQEIIGSGQFGLVHLGYWLN-----KDKVAIKTIREGA (SEQ ID NO:7)
TK_Src__BLK	LRLVRKLGSGQFGEVWVMGYKN-----NMKVAIKTLKEGT (SEQ ID NO:8)
TK_EGFR__EGFR	FKKIKVLGSGAFGTVYKGLWIPEGERVKIPVAIKELREAT (SEQ ID NO:9)
TK_EGFR__HER2_ErbB2	LKRVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENT (SEQ ID NO:10)
TK_EGFR__HER4_ErbB4	LKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETT (SEQ ID NO:11)
TK_JakA__JAK3	LKYISQLGKGNFGSVELCRYDPLAHNTGALVAVKQLQHSG (SEQ ID NO:12)
TK_Tec__BTK	--MSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQR-PIFI (SEQ ID NO:13)
TK_Tec__BMX	--MSEDEFFQEAQTMMKLSHPKLVKFGVCSKEY-PIYI (SEQ ID NO:14)
TK_Tec__TEC	--MCEEDFIEEAKVMMKLTHPKLVQLYGVCTQKQ-PIYI (SEQ ID NO:15)
TK_Tec__TXK	--MSEEDFIEEAKVMMKLSHSHKLVQLYGVCIQRK-PLYI (SEQ ID NO:16)
TK_Tec__ITK	--MSEEDFIEEAEVMMKLSHPKLVQLYGVCCLEQA-PICL (SEQ ID NO:17)
TK_Src__BLK	--MSPEAFLGEANVMKALQHERLVRLYAVVTKE---PIYI (SEQ ID NO:18)
TK_EGFR__EGFR	SPKANKEILDEAYVMASVDNPHVCRLLGICLTS---TVQL (SEQ ID NO:19)
TK_EGFR__HER2_ErbB2	SPKANKEILDEAYVMAGVSPYVSRLLGICLTS---TVQL (SEQ ID NO:20)
TK_EGFR__HER4_ErbB4	GPKANVEFMDEALIMASMDHPLVRLLVCLSP---TIQL (SEQ ID NO:21)
TK_JakA__JAK3	-PDQQRDFQREITQILKALHSDFIVKYRGSVSYGPRPELRL (SEQ ID NO:22)
TK_Tec__BTK	ITEYMANGCLLN YLREMRH-RFQTQQLEMCCKDV----- (SEQ ID NO:23)
TK_Tec__BMX	VTEYISNGCLLN YLRSHGK-GLEPSQLLEMICYDV----- (SEQ ID NO:24)
TK_Tec__TEC	VTEFMERGCLLN FLRQRQG-HFSRDVLLSMCQDV----- (SEQ ID NO:25)
TK_Tec__TXK	VTEFMENGCLLN YLRENKG-KLRKEMLLSVCQDI----- (SEQ ID NO:26)
TK_Tec__ITK	VTEFMEHGCLSD YLRTRQG-LFAAETLLGMCLDV----- (SEQ ID NO:27)
TK_Src__BLK	VTEYMARGCLLD FLKTDDEGSRLSLPRLIDMSAQIAEGMAY (SEQ ID NO:28)
TK_EGFR__EGFR	ITQLMPFPGCLLD YVREHKD-NIGSQYLLNWCVQIAKGMY (SEQ ID NO:29)
TK_EGFR__HER2_ErbB2	VTQLMPYGCCLLD HVRENRG-RLGSQDLLNWCMIKAGMSY (SEQ ID NO:30)
TK_EGFR__HER4_ErbB4	VTQLMPHGCCLLE YVHEHKD-NIGSQYLLNWCVQIAKGMY (SEQ ID NO:31)
TK_JakA__JAK3	VMEYLPSPGCLRD FLQRHRA-RLDASRLLLYSSQICKGMEY (SEQ ID NO:32)
TK_Tec__BTK	-----FLHRDLAARNCLVNDQGVVVKVS DFGL SRVLDDEY (SEQ ID NO:33)
TK_Tec__BMX	-----FIHRDLAARNCLVDRDLCVKVS DFGM TRYVLDDEY (SEQ ID NO:34)
TK_Tec__TEC	-----FIHRDLAARNCLVSEAGVVVKVS DFGM ARYFLDDQY (SEQ ID NO:35)
TK_Tec__TXK	-----YIHRDLAARNCLVSTCIVKIS DFGM TRYVLDDEY (SEQ ID NO:36)
TK_Tec__ITK	-----VIHRDLAARNCLVGENQVIKVS DFGM TRFVLDDEY (SEQ ID NO:37)
TK_Src__BLK	IERMNSIHRDLAARNILVSEALCCKIA DFGL AR-IIDSEY (SEQ ID NO:38)
TK_EGFR__EGFR	LEDVRLVHRDLAARNVLVKTTPQHVKIT DFGL LAKLLGAEEK (SEQ ID NO:39)
TK_EGFR__HER2_ErbB2	LEDVRLVHRDLAARNVLVKS ^{PNHVKIT} DFGL LARLLDIDET (SEQ ID NO:40)
TK_EGFR__HER4_ErbB4	LEBRLVHRDLAARNVLVKS ^{PNHVKIT} DFGL LARLLLEGDEK (SEQ ID NO:41)
TK_JakA__JAK3	LGSRRCVHRDLAARNILVESEAHVKIA DFGL LAKLLPLDKD (SEQ ID NO:42)

INTRACELLULAR KINASE INHIBITORS

[0001] This application is a continuation of Ser. No. 11/750,866 filed on May 18, 2007, which claims the benefit of provisional application Ser. No. 60/801,074 filed May 18, 2006 and Ser. No. 60/869,664 filed Dec. 12, 2006.

[0002] This application incorporates by reference the contents of a 25.1 kb text file created on Jun. 30, 2011 and named "sequencelisting.txt," which is the sequence listing for this application.

FIELD OF THE INVENTION

[0003] The invention relates to intracellular kinase inhibitors and their therapeutic uses.

BACKGROUND OF THE INVENTION

[0004] Intracellular kinases play important functions in cells of the immune system. For example, interleukin-2 inducible tyrosine kinase (ITK) plays a key role in T cell development and differentiation; it regulates IL-2 production via phospholipase C γ 1 (PLC γ 1) and nuclear factor of activated T cells (NFAT); it mediates Th2 cell differentiation; and it regulates T cell migration and recruitment to lymphatic organs. Bruton's tyrosine kinase (BTK) is involved in signal transduction pathways which regulate growth and differentiation of 13 lymphoid cells. BTK also is involved in platelet physiology by regulating the glycoprotein VI/Fc receptor γ chain (GPVI-FcR γ)-coupled collagen receptor signaling pathway. For these reasons, inhibitors of intracellular kinases are useful for treating blood cell malignancies, solid tumors and for suppressing the immune system, for example in patients with autoimmune disorders or organ transplants. Intracellular kinase inhibitors also are useful for preventing or reducing the risk of thromboembolism.

BRIEF DESCRIPTION OF THE DRAWING

[0005] FIG. 1. Results of a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor and evaluated for its ability to bind and dissociate from a small molecule.

[0006] FIG. 2. Alignment of human ITK (SEQ ID NO:1) and BTK (SEQ ID NO:2).

[0007] FIG. 3. Alignment of kinase domains. Bolded amino acids, hinge; bolded and underlined amino acids, gatekeeper; italicized and bolded amino acids, Cys442 equivalents.

DETAILED DESCRIPTION OF THE INVENTION

[0008] The invention provides compounds which inhibit intracellular kinases, particularly ITK and BTK, with an IC₅₀ of 1 μ M or below in an in vitro kinase assay as disclosed herein. The invention also provides pharmaceutical compositions and methods of using the compounds therapeutically. Patients who can be treated include those with blood cell malignancies, solid tumors, autoimmune disorders, and transplanted organs.

[0009] A review of the literature and patent database revealed the existence of compounds that inhibit ITK or BTK kinases. However, these compounds differ significantly from the compounds disclosed herein. In several instances, the compounds are pyrrolopyridines (e.g., US 2005/0215582). In other instances, the compounds are methyl dimethylbenzoates that belong thiazolyl family of compounds (e.g., US

2004/0077695). In all cases, these published compounds differ from the compounds disclosed herein based on the following parameters: the compounds do not correspond to the general structure shown in this application, do not require the amino acid triad DKC found in the kinase binding site and necessary for optimal compound inhibitory capability described herein, do not undergo elimination, and do not bind covalently to the kinase binding pocket.

[0010] Compounds of the invention which inhibit ITK can be used, e.g., to treat T cell malignancies. Preferred compounds of the invention inhibit both ITK and BTK with an IC₅₀ of 1 μ M or below for each enzyme. Such compounds can be used, e.g., to treat both T and B cell malignancies, as well as EGFR or HER positive tumors.

[0011] The Tec family of kinases share a common subunit structure composed of a Src homology domain 2 (SH₂), an SH₃ and a catalytic kinase domain. Further, they are uniquely identified by the presence of a Tec homology region (TH) and a pleckstrin homology (PH) domain. There are four known crystallographic structures described for the Tec family of kinases. These include (a) two structures representing the phosphorylated and unphosphorylated staurosporine-bound ITK (PDB codes 1 SM2, 1SNU); (b) one structure of the unphosphorylated apo-form of ITK (PDB code 1SNX), and (c) one structure for the unphosphorylated apo-form of BTK (Mao et al. *J. Biol. Chem.* 2001, 276, 41435-41443). For the purpose of clarity of explanation, this disclosure will represent these kinase structures with those of the nearly identical ITK structures in (a) and (b) incorporated herein by reference (Brown et al. *J. Biol. Chem.* 2004, 279, 18727-18732) focusing attention on the ATP binding site. For the sake of uniformity, the residue numbering in these kinase structures as represented in the Protein Data Bank have been incorporated throughout this document to describe the kinase domain. The amino acid sequence of human ITK is shown in SEQ ID NO:1. The amino acid sequence of human BTK is shown in SEQ ID NO:2. Homologous residues in the other kinases and sequences from other sources may be numbered differently.

[0012] Referring to FIG. 2, The ITK kinase domain (residues 357-620) can be broken down into two components: the N-terminal lobe (residues 357-437) and the C-terminal lobe (residues 438-620). Like most kinases, the connecting region between the two lobes is a flexible hinge region described below, that forms part of the catalytic active site. The ordered nature of the C-helix places the catalytically important residues of Glu406, Lys391 and Asp500 in an orientation typical of the active form of a protein kinase. The Gly-rich loop (residues 362-378), commonly observed in kinases, assumes an extended and open conformation typical of an active kinase.

[0013] The boundaries of the ATP binding site are demarcated by the following residues: (a) the glycine-rich loop (Gly370, Ser371, Gly372, Gln373, Phe374 and Gly375); (b) the hinge region (Phe435, Glu436, Phe437, Met438, Glu439, His440, Gly441 and Cys442); and (c) the catalytic residues Lys391 and Asp500. Additionally, the active site also comprises several other hydrophobic residues including Ala389, Ile369, Val377, Val419, and Leu 489 as well as the hydrophilic residue Ser499.

[0014] Similar to other kinases, the hinge region of ITK contains two backbone carbonyls and one backbone amino group as potential hydrogen bond acceptor and donor sites respectively. Similar backbone interactions have been observed in the interaction of kinases with the adenine base of

ATP and several competitive inhibitors have been designed pursuing this concept. At the N-terminal end of the hinge region lies the “gatekeeper” residue, Phe435. This residue blocks access to an internal hydrophobic pocket, and, at the same time, provides a potential site of interaction for aromatic or hydrophobic groups. This “gatekeeper” residue is a significant difference between ITK and BTK. Despite the strong overall sequence identity between BTK and ITK, the presence of the smaller threonine residue as a gatekeeper in the active site of BTK justifies a key similarity of the latter to the active site of several kinases such as Src/Ab/EGFR. The absence of the bulkier Phe gatekeeper allows access to an internal hydrophobic pocket for these kinases, a fact that has been exploited for the design of allosteric inhibitors, and to improve the affinity of ATP-competitive inhibitors through the addition of a hydrophobic pharmacophore.

Definitions

[0015] “Alkyl” is a monovalent linear or branched saturated hydrocarbon radical and can be substituted or unsubstituted. Linear or branched alkyls typically have between 1 and 12 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). Lower alkyls, or “C₁-C₆ alkyls,” have between 1 and 6 carbon atoms (e.g., 1, 2, 3, 4, 5, or 6). Optional substituents include halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trihaloalkylsulfonylamino (e.g., trifluoromethylsulfonylamino), arylthio, arylsulfinyl, arylsulfonyl, and heterocyclyl. Examples of linear or branched C₁-C₆ alkyl are methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, n-butyl, n-pentyl, sec-pentyl, tert-pentyl, n-hexyl, isopentyl, fluoromethyl, trifluoromethyl, hydroxybutyl, dimethylcarboxyalkyl, aminoalkyl, and benzylpropyl.

[0016] “Acyl” (or “alkylcarbonyl”) is the radical —C(O)R⁸, wherein R⁸ is an optionally substituted lower alkyl. Examples of acyl include, but are not limited to, acetyl, propionyl, n-butyryl, sec-butyryl, t-butyryl, iodoacetyl, and benzylacetyl.

[0017] “Acyloxy” is the radical —OC(O)R⁸, wherein R⁸ is an optionally substituted lower alkyl. Examples of acyloxy include, but are not limited to, acetoxyl, propionyl, butyryloxy, trifluoroacetoxyl, and diiodobutyryloxy.

[0018] “Alkoxy” is the radical —OR⁸, wherein R⁸ is an optionally substituted lower alkyl. Examples of alkoxy include methoxy, ethoxy, propoxy, 2-propoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, fluoromethoxy, and iodoethoxy.

[0019] “Alkylamino” is the radical —NR⁷R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylamino groups are methylamino, ethylamino, isopropylamino, dimethylamino, diethylamino, and trifluoromethylamino.

[0020] “Alkylaminocarbonyl” (or “alkylcarbamoyl”) is the radical —C(O)NR⁷R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylaminocarbonyl include, but are not limited to, methylaminocarbonyl, dimethylaminocarbonyl, t-butylaminocarbonyl, n-butylaminocarbonyl, iso-propylaminocarbonyl, and trifluoromethylaminocarbonyl.

[0021] “Alkylaminosulfonyl” is the radical —S(O)₂NR⁷R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylaminosulfonyl include, but are not limited to, methylaminosulfonyl, dimethylaminosulfonyl, and triiodomethylaminosulfonyl.

[0022] “Alkoxy carbonyl” or “alkyl ester” is the radical —C(O)OR⁸, wherein R⁸ is an optionally substituted lower alkyl. Examples of alkoxy carbonyl radicals include, but are not limited to, methoxy carbonyl, ethoxy carbonyl, sec-butoxy carbonyl, isopropoxy carbonyl, and difluoromethoxy carbonyl.

[0023] “Alkylcarbonylamino” is the radical —NR⁷C(O)R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylcarbonylamino include, but are not limited to, methylcarbonylamino, iso-propylcarbonylamino, and t-butylcarbonylamino.

[0024] “Alkylcarboxamido” is the radical —C(O)NR⁷R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylcarboxamidos are methylcarboxamido, ethylcarboxamido, isopropylcarboxamido, and n-propylcarboxamido.

[0025] “Alkylsulfonyl” is the radical —S(O)₂R⁸, wherein R⁸ is an optionally substituted lower alkyl. Examples of alkylsulfonyl include, but are not limited to, methylsulfonyl, trifluoromethylsulfonyl, and propylsulfonyl.

[0026] “Alkylsulfonylamino” is the radical —NR⁷S(O)₂R⁸, wherein R⁷ is hydrogen or an optionally substituted lower alkyl and R⁸ is an optionally substituted lower alkyl. Examples of alkylsulfonylamino include, but are not limited to, methylsulfonylamino, propylsulfonylamino, and trifluoromethylsulfonylamino.

[0027] “Aryl” is the monovalent aromatic carbocyclic radical of one individual aromatic ring or two or three fused rings in which at least one of the fused rings is aromatic. Aryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl, N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamidoalkyl, N,N-dialkylcarboxamidoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of aryls are phenyl, naphthyl, tetrahydronaphthyl, indanyl, indanonyl, tetralinyl, tetralonyl, fluorenyl, phenanthryl, anthryl, and acenaphthyl.

[0028] “Arylalkoxy carbonyl” or “arylalkyl ester” is the radical —C(O)OR⁸X, wherein R⁸ is an optionally substituted lower alkyl and X is an optionally substituted aryl. Examples of aryloxy carbonyl radicals include, but are not limited to, benzyl ester, phenyl ethyl ester, and dimethylphenyl ester.

[0029] “Arylalkyl carbamoyl” is the radical —C(O)NHR⁸X, wherein R⁸ is an optionally substituted lower alkyl

and X is an optionally substituted aryl. Examples of arylalkylcarbonyl include, but are not limited to, benzylcarbonyl, phenylethylcarbonyl, and cyanophenylcarbonyl.

[0030] “Arylalkylcarbonyl” (or “aralkylcarbonyl”) is the radical $\text{—C(O)R}^s\text{X}$, wherein R^s is an optionally substituted lower alkyl and X is an optionally substituted aryl. Examples of arylalkylcarbonyl radicals include, but are not limited to, phenylacetyl and fluorophenylacetyl.

[0031] “Arylamino carbonyl” (or “arylcabonyl”) is the radical $\text{—C(O)NXX}'$, wherein X is an optionally substituted aryl and X' is hydrogen or an optionally substituted aryl. Examples of arylamino carbonyl include, but are not limited to, phenylamino carbonyl, methoxyphenylamino carbonyl, diphenylamino carbonyl, and dimethoxyphenyl-amino carbonyl.

[0032] “Arylamino sulfonyl” is the radical $\text{—S(O)}_2\text{NXX}'$, wherein X is an optionally substituted aryl and X' is hydrogen or an optionally substituted aryl. Examples of arylamino sulfonyl include, but are not limited to, phenylamino sulfonyl, methoxyphenylamino sulfonyl, and triiodomethylamino sulfonyl.

[0033] “Arylcarbonyl” is the radical —C(O)X , wherein X is an optionally substituted aryl. Examples of arylcarbonyl radicals include, but are not limited to, benzoyl, naphthoyl, and difluorophenylcarbonyl.

[0034] “Arylcarbonylamino” is the radical —NHC(O)X , wherein X is an optionally substituted aryl. Examples of arylcarbonylamino include, but are not limited to, phenylcarbonylamino, tosylcarbonylamino, and cyanophenylcarbonylamino.

[0035] “Aryloxy” is —OX , wherein X is an optionally substituted aryl. Examples of aryloxy include phenyloxy, naphthyloxy, tetrahydronaphthyloxy, indanyloxy, indanonyloxy, biphenyloxy, tetralinyloxy, tetralonyloxy, fluorenyloxy, phenanthryloxy, anthryloxy, and acenaphthyloxy.

[0036] “Aryloxy carbonyl” or “aryl ester” is the radical —C(O)OX , wherein X is an optionally substituted aryl. Examples of aryloxy carbonyl radicals include, but are not limited to, phenyl ester, naphthyl ester, dimethylphenyl ester, and trifluorophenyl ester.

[0037] “Arylsulfonyl” is the radical $\text{—S(O)}_2\text{X}$, wherein X is an optionally substituted aryl. Examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, nitrophenylsulfonyl, methoxyphenylsulfonyl, and 3,4,5-trimethoxyphenylsulfonyl.

[0038] “Arylsulfonylamino” is the radical $\text{—NS(O)}_2\text{X}$, wherein X is an optionally substituted aryl. Examples of arylsulfonylamino include, but are not limited to, phenylsulfonylamino, naphthylsulfonylamino, 2-butoxyphenylsulfonylamino, 4-chlorophenylsulfonylamino, 2,5-diethoxysulfonylamino, 4-hexyloxyphenylsulfonylamino, 4-methylphenylsulfonyl-amino, naphthylsulfonylamino, 4-methoxyphenylsulfonylamino, N-methylphenylsulfonylamino, and 4-cyanophenylsulfonylamino, phenylsulfonylamino, 4-methylphenylsulfonyl-amino, naphthylsulfonylamino, phenylsulfonylamino, and 4-methylphenylsulfonylamino.

[0039] “Arylsulfonyloxy” is the radical $\text{—OS(O)}_2\text{X}$, wherein X is an optionally substituted aryl. Examples of arylsulfonyloxy include, but are not limited to, benzenesulfonyloxy and 4-chloro-benzenesulfonyloxy.

[0040] “Cycloalkyl” is a monovalent saturated carbocyclic radical consisting of one or more rings, preferably one, of three to seven carbons per ring and can be optionally substi-

tuted with one or more of hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbonyl, arylcarbonyl, aminocarbonyl, N-alkylaminocarbonyl, N,N-dialkylaminocarbonyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbonylalkyl, arylcarbonylalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl, N,N-dialkylaminocarbonylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamidoalkyl, N,N-dialkylcarboxamidoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, cycloheptyl, tetrahydro-naphthalene, methylenecyclohexyl, indanyl, indenyl, and fluorenyl.

[0041] “Cycloalkylcarbonyl” is the radical —C(O)R , wherein R is an optionally substituted cycloalkyl radical. Examples of cycloalkylcarbonyl radicals include, but are not limited to, cyclobutanoyl, cyclopentanoyl, cyclohexanoyl, and trifluorocyclopentanoyl.

[0042] “Halogen” includes fluorine, chlorine, bromine, and iodine.

[0043] “Heteroaryl” is a monovalent aromatic cyclic radical having one or more rings, preferably one to three rings, of four to eight atoms per ring, incorporating one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur. Heteroaryls can be optionally substituted on one or more rings with one or more of halogen, hydroxyl, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylcarbonyl, arylcarbonyl, aminocarbonyl, N-alkylaminocarbonyl, N,N-dialkylaminocarbonyl, alkylsulfonylamino, arylsulfonylamino, carboxy, carboxyalkyl, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbonylalkyl, arylcarbonylalkyl, aminocarbonylalkyl, N-alkylaminocarbonylalkyl, N,N-dialkylaminocarbonylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxy, alkylcarboxyalkyl, N-alkylcarboxamidoalkyl, N,N-dialkylcarboxamidoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, trifluoromethylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl.

[0044] Representative examples of monocyclic ring system heteroaryls include, but are not limited to, azetidiny, azepiny, aziridiny, imidazepiny, 1,3-dioxolany, dioxany, dithianyl, furyl, imidazolyl, imidazoliny, imidazolidiny, isothiazolyl, isothiazoliny, isothiazolidiny, isoxazolyl, isoxazoliny, isoxazolidiny, morpholiny, oxadiazolyl, oxadiazoliny, oxadiazolidiny, oxazolyl, oxazoliny, oxazolidiny, piperaziny, piperidiny, pyranyl, pyraziny, pyrazolyl, pyrazoliny, pyrazolidiny, pyridyl, pyrimidiny, pyridaziny, pyrroly, pyrroliny, pyrrolidiny, tetrahydrofuranly, tetrahydrothiophenyl, tetraziny, tetrazolyl, thiadiazolyl, thiadiazoliny, thiadiazolidiny, thiazolyl, thiazoliny, thiazolidiny, thiophenyl, thiomorpholiny, 1,1-dioxidothiomorpholiny, thiopyranly, triaziny, triazolyl, and trithianly.

[0045] Bicyclic ring systems include any of the above monocyclic ring systems fused to an aryl group, a cycloalkyl group, or another heteroaryl monocyclic ring system. Representative examples of bicyclic ring systems include but are not limited to, benzimidazolyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothioapyranyl, benzodioxinyl, 1,3-benzodioxolyl, cinnolinyl, indazolyl, indolyl, indolinyl, indoliziny, naphthyridinyl, isobenzofuranyl, isobenzothiophenyl, isoindolyl, isoindolinyl, isoquinolyl, phthalazinyl, pyranopyridyl, quinolyl, quinoliziny, quinoxaliny, quinazoliny, tetrahydroisoquinolyl, tetrahydroquinolyl, and thiopyranopyridyl.

[0046] Tricyclic rings systems include any of the above bicyclic ring systems fused to an aryl group, a cycloalkyl group, or a heteroaryl monocyclic ring system. Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzofuranyl, dibenzothiophenyl, naphthofuranyl, naphthothiophenyl, oxanthrenyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phenothiazinyl, thianthrenyl, thioxanthinyl, and xanthenyl.

[0047] "Heteroarylaminocarbonyl" is the radical $-C(O)NZZ'$, wherein Z is an optionally substituted heteroaryl and Z' is hydrogen or an optionally substituted heteroaryl. Examples of heteroarylaminocarbonyl include, but are not limited to, pyridinylaminocarbonyl, and thienylaminocarbonyl, furanylaminocarbonyl.

[0048] "Heteroarylaminosulfonyl" is the radical $-S(O)_2NZZ'$, wherein Z is an optionally substituted heteroaryl and Z' is hydrogen or an optionally substituted heteroaryl. Examples of heteroarylaminosulfonyl include, but are not limited to, thienylaminosulfonyl, piperidinylamino sulfonyl, furanylaminosulfonyl, and imidazolylaminosulfonyl.

[0049] "Heteroarylcarbonyl" is the radical $-C(O)Z$, wherein Z is an optionally substituted heteroaryl. Examples of heteroarylcarbonyl radicals include, but are not limited to, pyridinoyl, 3-methylisoxazoloyl, isoxazoloyl, thienyl, and furoyl.

[0050] "Heteroarylsulfonyl" is the radical $-S(O)_2Z$, wherein Z is an optionally substituted heteroaryl. Examples of heteroarylsulfonyl include, but are not limited to, thienylsulfonyl, furanylsulfonyl, imidazolylsulfonyl, and N-methylimidazolylsulfonyl.

[0051] "Heteroarylsulfonyloxy" is the radical $-OS(O)_2Z$, wherein Z is an optionally substituted heteroaryl. An examples of hetroarylsulfonyloxy is thienylsulfonyloxy.

[0052] "Heterocycle" is a saturated or partially unsaturated carbocyclic radical having one, two, or three rings each containing one or more heteroatoms selected independently from nitrogen, oxygen, silicon, and sulfur. A heterocycle can be unsubstituted or substituted on any or all of the rings with one or more of halogen, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, amino, N-alkylamino, N,N-dialkylamino, alkylsulfonylamino, arylsulfonylamino, alkylcarbamoyl, arylcarbamoyl, aminocarbamoyl, N-alkylaminocarbamoyl, N,N-dialkylaminocarbamoyl, carboxy, alkylcarboxy, N-alkylcarboxamido, N,N-dialkylcarboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoromethylsulfonylamino, arylthio, arylsulfinyl, arylsulfonyl, carboxyalkyl, hydroxyalkyl, alkoxyalkyl, aryloxalkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, alkylcarbamoylalkyl, arylcarbamoylalkyl, aminocarbamoylalkyl, N-alkylaminocarbamoylalkyl, N,N-dialkylaminocarbamoylalkyl, alkylsulfonylaminoalkyl, arylsulfonylaminoalkyl, alkylcarboxyalkyl, N-alkylcarboxamidoalkyl, N,N-dialkylcarboxamidoalkyl, alkylthioalkyl,

alkylsulfinylalkyl, alkylsulfonylalkyl, trihaloalkylsulfonylaminoalkyl, arylthioalkyl, arylsulfinylalkyl, and arylsulfonylalkyl. Examples of heterocycles include piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiamorpholinyl, pyrrolyl, phthalamide, succinamide, and maleimide.

[0053] "Heterocyclylcarbonyl" (or "heterocyclocarbonyl") is the radical $-C(O)M'$, wherein M' is an optionally substituted heterocycle. Examples of heterocyclylcarbonyl include, but are not limited to, piperazinoyl, morpholinoyl, and pyrrolidinoyl.

[0054] "Heterocyclylsulfonyl" is the radical $-S(O)_2Z'$, wherein M' is an optionally substituted heterocycle. Examples of heterocyclylsulfonyl include, but are not limited to, piperidinylsulfonyl and piperazinylsulfonyl.

[0055] "Heterocyclylsulfonyloxy" is the radical $-OS(O)_2M'$, wherein M' is an optionally substituted heterocycle. Examples of heterocyclylsulfonyloxy include, but are not limited to, 3,5-dimethyl-isoxazolesulfonyloxy and pyrrolidinylsulfonyloxy.

Compounds

[0056] This invention provides compounds which inhibit tyrosine kinases, particularly Tec (e.g., ITK, BTK), Src (Src, Lck, etc.) and EGFR kinases (e.g., EGFR1, Her 2, Her 4), and Jak kinase (e.g., Jak3), having structures that exploit a discrete mechanistic rationale described herein. This mechanism provides for the utilization of the kinase catalytic machinery, described in the ITK crystallographic structures as the acid-base pair residues Lys391 and Asp500 (herein referred to as the "catalytic dyad"), to trigger a transformation that activates the proposed inhibitory compounds within the enzyme active site. This transformation involves the elimination of a leaving group, resulting in the in situ formation of an electrophilic intermediate capable of forming a covalent adduct with an active site cysteine residue thereby irreversibly inhibiting the function of the target enzyme. This cysteine residue is identifiable as Cys442 in the ITK crystallographic structure. The group of kinases with the above described triad, including ITK, BTK, BMX, Tec, TXK, BLK, EGFR, Her 2, Her 4 and JAK3, will be referred to as the DKC triad kinases. Various embodiments of the invention relate to this group, its possible sub-groupings, and to its individual members.

[0057] It is known that several compounds, typically containing electrophilic Michael acceptors, form covalent adducts with enzymatic nucleophiles present in the active site to irreversibly inhibit the target enzyme (Slichenmeyer, W. J.; Elliott, W. C.; Fry, D. W. *Semin. Oncol.* 2001, 28, 80-85; Shimamura, T.; Ji, H.; Minami, Y.; Thomas, R. K.; Lowell, A. M.; Sha, K.; Greulich, H.; Glatt, K. A.; Meyerson, M.; Shapiro, I.; Wong, K.-K. *Cancer Res.* 2006, 66, 6487-6491). However, the compounds described in this invention are unique in that the transformation that forms the electrophilic intermediate takes place preferentially in situ, i.e. within the enzyme active site. Outside of an appropriate active site, these compounds are much less likely to undergo beta-elimination and form adducts with other proteins. The compounds described within must first bind in the active site of the target kinase and achieve a specific conformational geometry with respect to the relevant catalytic residues in order to effectively trigger elimination of the leaving group, thereby unmasking the adduct-forming intermediate. This intermediate forms a covalent, irreversible adduct with the proximal active site cysteine residue. In some embodiments the reaction proceeds

stepwise; in other embodiments it is concerted. In preferred embodiments additional portions of the inhibitor molecule interact with other portions of the kinase, particularly in the active site, to promote favorable binding affinity and positioning. Such interactions contribute to the specificity of various inhibitors so that some inhibitors inhibit a single kinase whereas others inhibit multiple kinases with similar or different IC₅₀s. To our knowledge, this is the first example of an in situ formation of an active inhibitor in a kinase active site.

Compound Interaction with the Kinase Domain

[0058] Without specifying the kinetics of the reaction, the inhibition of the target kinase goes through the following sequence of steps to form the adduct with the inhibitory compounds:

[0059] (1) The catalytic lysine N—H is positioned within hydrogen bonding distance (approximately 1.8-4.0 Angstroms) of a hydrogen bond acceptor Y in the compound that exists in the form of a C=Y (Y=O, S, NOR) functionality. Polarization of the C=Y bond results in increasing the acidity of the proton (H_A) at a carbon atom alpha to the C=Y group.

[0060] (2) Acting as a base, the aspartate of the catalytic dyad extracts the acidic proton H_A, leaving behind a conjugated carbanion that forms for Y=O, an enol, H-bonded enolate through standard electronic rearrangement. For Y=S, it would form a thioenol or H-bonded thioenolate, and for Y=NOR, it would form an alkoxy (R=alkyl), aryloxy (R=aryl) or hydroxy (R=H) enamine.

[0061] (3) The formation of the enol/thioenol/enamine facilitates the elimination of the leaving group attached at a carbon beta to C=Y, through a process known as “β-elimination.” The leaving group, attached to the compound through protonatable heteroatom Z, may optionally be additionally tethered to the rest of the compound.

[0062] (4) Being a strong nucleophilic species, the sulfhydryl group of the neighboring cysteine residue reacts with the newly formed electrophilic elimination product. This addition reaction (thioalkylation) forms the covalent adduct to the kinase resulting in its irreversible inhibition and abrogation of activity.

[0063] The inhibitory activity of this class of compounds toward select kinases is dependent on their ability to bind effectively in proximity to the appropriate catalytic environment, the existence of a polarizable C=Y group (C=O in formula (I), below) with appropriate reactivity and an adjacent alpha proton to allow elimination of the beta leaving group.

[0064] In turn, the elimination process that generates a reactive electrophilic species requires removal of the abstractable alpha proton that is facilitated by adequate positioning of the C=Y group in the catalytic environment. The generated electrophilic Michael acceptor, in turn is required to be positioned within reactive distance of the key cysteine residue.

[0065] The appropriate positioning of the abstractable proton in the kinase binding site is achieved through pharmacophoric elements that include:

[0066] (i) a C=Y moiety that serves the dual purpose of polarizing the proximal C—H bond of the abstractable proton, and hydrogen bonding to the lysine residue of the catalytic pair;


[0067] (ii) a hydrophobic aryl or heteroaryl group that interacts with specific hydrophobic residues in the binding site at an approximate distance of 3-5 Å from Y,

[0068] (iii) several (one to 3) hydrophilic pharmacophores that interact with the backbone in the hinge region,

[0069] (vi) a carbon atom in the beta position from the C=Y carbon atom, that is positioned within reactive distance of the sulfhydryl group of the relevant cysteine as explained below.

[0070] The effective “reactive distance” to the cysteine sulfhydryl group as stated above is observed in the range of about 3-10 Å using computational design methods that test the binding of inhibitors to the ITK ATP binding site, wherein the enzyme is maintained in a fixed conformation. While a distance of 10 Å in a rigid system would be too far to effect a chemical reaction, the enzymatic nucleophilic moiety and the inhibitor’s electrophilic moiety can readily be brought together through a series of low energy barrier rotations around the flexible inhibitor bonds as well as the cysteinyl side chain. Overall global conformational changes, common to kinase systems, cannot be ruled out either but are not readily measurable. Such conformational changes, which can be envisioned by computational predictions, are adequate in bringing the two reactive pieces in close enough proximity to effect covalent bond formation.

[0071] Compounds according to the invention have the structural formula:




wherein:

Ar is optionally substituted aryl or optionally substituted heteroaryl;


R³, R⁴, R⁵, and R⁶ are independently hydrogen or optionally substituted C₁-C₆ alkyl; and

R¹ and R² (a) are independently hydrogen, optionally substituted C₁-C₆ alkyl, piperidine, or furanyl; or (b) are taken together with the nitrogen atom to which they are attached to form (i) a 5- to 7-membered optionally substituted aryl, (ii) a 5- to 7-membered optionally substituted heteroaryl, or (iii) a 5- to 7-membered optionally substituted heterocycle which may be unfused or fused to an optionally substituted aryl.

[0072] In some embodiments Ar is selected from the group consisting of:




-continued




wherein A, B, E, and Q are independently CH, O, or N; and D and D' are independently CH₂, NH, O, or S.


[0073] In other embodiments Ar is selected from the group consisting of:



[0074] Examples of 5- to 7-membered heterocycles include:



-continued



wherein:

G is N, CH, or S;

G' is NH, CH, or S;


[0075] $n=0-2$;

R¹ and R² are as defined above; and

R⁷ is hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted aryl, or optionally substituted heteroaryl.

[0076] Preferred 5- to 7-membered heterocycles are piperazinyl, piperidinyl, pyrrolidinyl, and morpholinyl. Preferred substituents for piperazinyl are C₁-C₆ alkyl, dialkyl C₁-C₆ aminoalkyl, aryl, aralkyl, cycloalkyl, and cycloalkyl-alkyl. Preferred substituents for piperidinyl are C₁-C₆ alkyl and aralkyl. In some embodiments piperidinyl is benzofused to form isoquinolinyl. Preferred substituents for pyrrolidinyl are C₁-C₆ alkyl, aryl, and aralkyl. In some embodiments pyrrolidinyl is benzofused to form isoindolyl. Preferred substituents for morpholinyl are C₁-C₆ alkyl and arylalkyl.


[0077] Some compounds have the structural formula:





(II)

wherein:

[0078] R³, R⁴, R⁵, and R⁶ are as defined above; R⁹ is selected from,






and


[0079] R¹⁰ is hydrogen, —OH, —COOH, —CONH₂, or —NCO,

[0080] wherein if R⁹ is naphthyl, then R⁵ and R⁶ are not both methyl.


[0081] Examples of these compounds include:











-continued











-continued




-continued




-continued



-continued




-continued



[0082] Other compounds have the structural formula:

(III)




wherein:


[0083] R³, R⁴, R⁵, and R⁶ are as defined above;

[0084] R¹¹ and R¹² are independently selected from hydrogen, —OCH₃, halogen, —NO₂, —CN, —CF₃, —NCOR' (wherein R' is hydrogen or C₁-C₄ alkyl), phenoxy, —OCF₃, —NR'R'' (wherein R' and R'' are independently hydrogen or C₁-C₄ alkyl), C₁-C₄ alkoxy, and —SO₂R' (wherein R' is hydrogen or C₁-C₄ alkyl); and


[0085] R¹³ is hydrogen, C₁-C₄ alkyl,




with the proviso that formula (III) does not include the following compounds:




-continued







[0086] One example of a compound of formula (III) is




[0087] Some compounds of the invention have the structural formula:



wherein R^1 and R^2 are as defined above, with the exception of




[0088] Examples of such compounds include those of with the following structural formulae:



in which:

[0089] GG is hydrogen, dimethylaminoalkyl, aryl, C_1 - C_6 alkyl, cyclohexylalkyl, pyridine, $-COCF_3$, $-CONR'R''$, or




[0090] J is hydrogen, aralkyl, C_1 - C_6 alkyl, $-CNH-COOR'$, or $NR'R''$;


[0091] K is hydrogen, pyridine, aryl, $-COOH$, $-CONR'R''$, $-COH$, or $-CNR'R''$;

[0092] L is hydrogen or alkyloxy; and


[0093] R^2 is as defined above.

[0094] Other compounds of formula (IV) include:






[0095] Other compounds have the structural formula:



wherein R^3 , R^4 , R^5 , R^6 , and R^{10} are as defined above.

[0096] Other compounds have the structural formula:



wherein:


[0097] R^1 , R^2 , R^3 , R^4 , R^5 , and R^6 are as defined above;

and


[0098] R^{14} is hydrogen or =O;

[0099] and D is CH or NH,

with the exception of:



[0100] Other compounds have the structural formula:




(VII)

wherein:


[0101] R^3 , R^4 , R^5 , and R^6 are as defined above; and

[0102] R^1 and R^2 are independently hydrogen, C_1 - C_4 alkyl,




(V)

(wherein R^{15} is halogen or C_1 - C_4 alkyl and R^{16} is C_1 - C_4 alkyl), or R^1 and R^2 together with the nitrogen to which they are attached form an aryl group selected from




(VI)


(wherein R^{17} and R^{18} are independently hydrogen or $-OCH_3$),




(wherein R¹ and R² are independently hydrogen or C₁-C₄ alkyl),



(n=1-4), phenyl-C₁-C₄ alkyl (optionally substituted with halogen), with the exception of




[0103] Other compounds have the structural formula:




wherein R³, R⁴, R⁵, and R⁶ are as defined above.


[0104] Other compounds have the structural formula:




wherein R³, R⁴, R⁵, and R⁶ are as defined above and wherein R¹ is hydrogen and R² is



wherein R¹⁹ is selected from hydrogen and




or R¹ and R² together with the nitrogen to which they are attached are




A is N or O;

[0105] R²⁰ is phenyl-C₁-C₄ alkyl optionally substituted with one or more halogens, hydrogen, C₁-C₄ alkyl, amino-C₁-C₄ alkyl,




R¹⁷ and R¹⁸ are independently hydrogen or —OCH₃; R²¹ is —CONR'R'', —COR',



and


R' and R'' are independently selected from hydrogen and C₁-C₄ alkyl.

[0106] In other embodiments compounds have the structural formula:




wherein R^3 , R^4 , R^5 , and R^6 are as defined above and wherein R^{22} is selected from hydrogen, C_1 - C_4 alkyl, $-NR'R''$, $-COH$, $-COOH$, $-CNR'R''$, and $-CONHR'$, wherein R' and R'' are as defined above.

[0107] In other embodiments compounds have the structural formula:




wherein R^3 , R^4 , R^5 , R^6 , G , and G' are as defined above; and R^{23} is hydrogen, $-NR'R''$, C_1 - C_4 linear alkyl, C_1 - C_4 alkyl, phenyl- C_1 - C_4 alkyl, $-CONH_2$, and $-COR'R''$, wherein R' and R'' are as defined above.


[0108] In other embodiments compounds have the structural formula:




R^3 , R^4 , R^5 , and R^6 are as defined above and wherein R^{24} is



[0109] In other embodiments compounds have the structural formula:




wherein L is




and wherein R^3 , R^4 , R^5 , and R^6 are as defined above.


[0110] Some compounds have the structural formula:




wherein T, U, V, and W independently are selected from hydrogen; halogen; $-O$; C_1 - C_3 alkyl; and C_1 - C_3 alkyloxy; and wherein R^{25} is hydrogen or C_1 - C_3 alkyl. Representative compounds include:



and




[0111] Other compounds have the structural formula:



(XV)

wherein T, U, V, and W independently are selected from hydrogen; halogen; —O; C₁-C₃ alkyl; and C₁-C₃ alkyloxy; and wherein R⁸ is hydrogen or C₁-C₃ alkyl.


[0112] Still other compounds have the structural formula:



(XVI)



wherein T, U, V, and W independently are selected from hydrogen; halogen; —O; C₁-C₃ alkyl; and C₁-C₃ alkyloxy; and wherein R⁸ is hydrogen or C₁-C₃ alkyl.

[0113] Other compounds have the structural formula:




(XVII)

wherein D is S, O, or NH;





[0114] Other compounds of the invention include those with the structural formula:




(XVIII)


wherein D is defined above;



and




[0115] Other compounds of the invention include those with the structural formula:



(XIX)

wherein G' is NH or CH; i.e.,



[0116] The invention also includes the compounds identified in Examples 15 and 16.

[0117] The compounds of the present invention may have asymmetric centers and may occur as racemates, stereoisomers, and tautomers. The invention includes all possible racemates, tautomers, stereoisomers, and mixtures thereof


[0118] Suitable methods of preparing compounds of the invention are illustrated by the representative examples provided below. Starting materials are known compounds and can be obtained by standard procedures of organic chemistry.

[0119] Provisos for Compound Claims


[0120] Compounds of the invention preferably do not have one or more of the following activities: vasodilator, hypotensive, bradycardiac, anti-depressant, anti-arrhythmic, anti-arteriosclerotic, serum cholesterol lowering, triglyceride level lowering, neuroleptic, anti-inflammatory, tranquilizing, anti-convulsant, anesthetic, muscle relaxing, anti-fungal, anti-bacterial, insecticidal, fumigant, anti-parasitic, central nervous system depressant, antagonization of sedation, antipollakiurea, antihistamine, anti-allergy, bronchodilating, analgesic, spasmolytic, muscarinic antagonist, preventing or decreasing production of abnormally phosphorylated paired helical filament epitopes associated with Alzheimer's Disease, hypolipidemic, male anti-fertility, anti-sporicidal, inhibition of nitric oxide production, or central nervous system stimulant activities.

[0121] To the extent any of the following compounds are not novel, Applicants reserve the right to present compound and/or composition claims which include a proviso excluding the compounds and/or their pharmaceutically acceptable salts from the scope of the claims:

[0122] a. compounds having the structural formula:




[0123] wherein n is 0, 1, or 3 and R¹ and R² together with the nitrogen atom to which they are attached are




and Y is alkyl, halogen, halogenoalkyl, alkoxy, alkylthio, halogenoalkoxy, halogenoalkylthio, cycloalkyl, or a cyane radical;

[0124] b. compounds of formula (I) in which Ar is phenyl, if R³, R⁴, R⁵, and R⁶ are each hydrogen, and R¹ and R² together form a ring with the nitrogen atom to which they are attached




[0125] c. compounds having the structural formula:




[0126] in which Ph is an optionally substituted monocyclic carbocyclic aryl radical, Alk is C₁-C₃ lower alkyl, and Am is a tertiary amino group, salts, N-oxides, or quaternary ammonium derivatives thereof;

[0127] d. compounds having the structural formula:




[0128] in which Ph₁ and Ph₂ are monocyclic carboxylic an radicals and the acid addition salts thereof;

[0129] e. compounds having the structural formula:




[0130] in which RR is selected from the group consisting of aliphatic, aromatic, and araliphatic radicals; RR¹ is selected from the group consisting of hydrogen, aliphatic, aromatic, and araliphatic radicals; —N(XX) is the residue of a secondary amine selected from the group consisting of dialkylamine and dialkylamines;


[0131] f. compounds having the structural formula:



[0132] wherein R¹ and R² as defined in formula (I), including the compound




[0133] g. compounds having the structural formula:




[0134] wherein R³⁰ is an ethyl-, propyl-, isopropyl-, butyl-, or isobutyl group or a cycloalkyl group having 5-7 carbon atoms;

[0135] h. compounds having the structural formula:




[0136] in which M² is hydrogen, halogen, or C₁-C₁₂ alkoxy, M¹ is hydrogen or halogen, and M³ and M⁴ are lower alkyl or, taken together with the nitrogen atom to which they are attached, (a) are a heterocyclic amino group or an N-lower alkyl quaternary heterocyclic ammonium group or (h) a tri-lower alkyl-ammonium;

[0137] i. compounds having the structural formula:




[0138] or a picrate salt thereof, wherein M⁵ is a simple or substituted aryl group and M⁶ is a simple or substituted amino group;

[0139] j. compounds having the structural formula:



[0140] in which M⁷ is thienyl, phenyl or substituted phenyl,


[0141] k. compounds having the structural formula:




[0142] in which each of X¹, X², and X³ are independently hydrogen or an alkyl group, and each of X⁵ and X⁴ are independently hydrogen or an alkyl group or, together with the nitrogen atom to which they are attached, form a heterocyclic group with 5, 6, or 7 ring atoms, optionally containing, in addition to N, a further heteroatom selected from N, S, and O;

[0143] l. compounds of formula (II) in which R⁹ is phenyl and R³, R⁴, R⁵, and R⁶ are each hydrogen;


[0144] m. compounds having the structural formula:



[0145] in which X⁶ forms with the nitrogen atom pyrrolidine, piperidine, morpholine, hexamethyleneimine, 3-azabicyclo-3,2,2 nonane, including the compound




[0146] n. compounds having the structural formula:




[0147] in which X^7 is hydrogen or fluorine; X^8 is $N(X^9)$ phenyl (wherein the phenyl is optionally monosubstituted with C_1 - C_8 alkoxy, C_1 - C_8 alkyl, trifluoromethyl, or halogen), $-C(OH)(X^9)$ phenyl (wherein the phenyl is optionally monosubstituted with C_1 - C_8 alkoxy, C_1 - C_8 alkyl, trifluoromethyl, or halogen), or phenyl (wherein the phenyl is optionally monosubstituted with C_1 - C_8 alkoxy, C_1 - C_8 alkyl, trifluoromethyl, or halogen); and X^9 is hydrogen, C_1 - C_8 alkyl, or lower alkanoyl;

[0148] o. compounds having the structural formula:




[0149] wherein X^9 and X^{10} each designate a saturated or unsaturated aliphatic hydrocarbon having 1 to 4 carbon atoms or, together with the nitrogen to which they are attached, form a heterocyclic radical selected from pyrrolidino, piperidine, perhydroazepino, and morpholino;

[0150] p. compounds having the structural formula:



[0151] in which X^{11} is C_2 - C_3 alkyl;


[0152] q. compounds having the structural formula:



[0153] in which X^{11} is hydrogen, halogen, C_1 - C_4 alkoxy, nitro, or C_1 - C_4 secondary amine; X^{12} is $(CH_2)_nOX^{13}$; n is 2 or 3; and X^{13} is C_1 - C_4 alkoxyphenyl, nitrophenyl, trifluoromethylphenyl, or phenyl disub-


stituted with two halogens, two C_1 - C_4 alkyls, halogen and nitro, halogen and C_1 - C_4 alkyl, halogen and C_1 - C_4 alkoxy, or C_1 - C_4 alkoxy and C_1 - C_4 alkyl;

[0154] r. compounds having the structural formula:




[0155] in which X^{14} , X^{15} , and X^{16} are independently hydrogen, halogen, C_1 - C_4 alkyl, halogeno- C_1 - C_4 alkyl, C_1 - C_4 alkoxy, or a cycloalkyl group having 3-8 carbon atoms and two of X^{14} , X^{15} , and X^{16} may combine to form methylenedioxy or ethyleneoxy; X^{18} is hydrogen or C_1 - C_4 alkyl, and X^{17} is pyrrolidinyl-, morpholinyl-, or azepinyl;

[0156] s. compounds having the structural formula:




[0157] Ar denotes an aryl radical; and X^{19} and X^{20} (a) are both C_1 - C_6 alkyl or (b) together with the N atom form the remaining members of a saturated heterocyclic radical and X^{21} is $-OH$, C_1 - C_6 alkyl, or aryl;

[0158] t. compounds having the structural formula:




[0159] wherein R^1 and R^2 independently represent an alkyl radical; or R^1 and R^2 , together with the nitrogen atom to which they are bonded complete an optionally substituted heterocyclic radical of the formula




R^3 is hydrogen or C_1 - C_4 alkyl; and X^{22} , X^{23} , and X^{24} are independently alkyl; halogen, or a halogeno- C_1 - C_4 alkyl, C_1 - C_4 alkoxy, alkylthio, halogeno- C_1 - C_4 alkoxy, halogeno- C_1 - C_4 alkylthio, cycloalkyl 3 to 7 carbon atoms, or cyano;

[0160] u. compounds having the structural formula:




[0161] wherein Ar is non-substituted an or an substituted with a hydroxyl group, lower alkoxy group or halogen, or non-substituted benzo[b]thienyl group or benzo[b]thienyl group substituted by hydroxyl group, lower alkyl group, lower alkoxy group, aryl group or halogen; R⁵ is hydrogen or C₁-C₄ alkyl; and X²⁵ is a group other than piperidine;

[0162] v. compounds having the structural formula:




[0163] wherein L¹ and L² are independently halogen or alkyl; L⁶ and L⁷ are independently hydrogen or alkyl; and L³ and L⁴ are independently hydrogen or an aliphatic group or combine together with the nitrogen to which they are attached to form a ring;

[0164] w. compounds of formula (I), (IV), (VI), (VII), (IX), and (XI) in which if R³ and R⁴ are hydrogen, then




[0165] is not




wherein L⁸ is a carbonyl, sulfonyl, methylene, or methylene substituted with optionally substituted phenyl; and Ar is an aryl group;

[0166] x. compounds having the structural formula:



[0167] in which T¹ is O, S, or NT⁷; T⁷ is hydrogen, C₁-C₄ alkyl, and CH₂CH₂COAr₁; T⁶ is hydrogen, C₁-C₆ alkyl, or T⁶ and a substituent on the an group together represent CH₂, CH₂CH₂, CH₂O, or CH₂S to form a five or six membered ring where the ring is optionally substituted with C₁-C₆ alkyl or phenyl; T⁵ is hydrogen, C₁-C₆ alkyl, or optionally substituted phenyl; T², T³, and T⁴ are independently hydrogen or C₁-C₆ alkyl; and Ar and Ar₁ are aryl or optionally substituted phenyl; and

[0168] y. the following compounds:



Pharmaceutical Preparations

[0169] Compounds of the invention can be formulated as pharmaceuticals using methods well known in the art. Pharmaceutical formulations of the invention typically comprise at least one compound of the invention mixed with a carrier, diluted with a diluent, and/or enclosed or encapsulated by an ingestible carrier in the form of a capsule, sachet, cachet, paper or other container or by a disposable container such as an ampoule.

[0170] A carrier or diluent can be a solid, semi-solid or liquid material. Some examples of diluents or carriers which may be employed in the pharmaceutical compositions of the present invention are lactose, dextrose, sucrose, sorbitol, mannitol, propylene glycol, liquid paraffin, white soft paraffin, kaolin, microcrystalline cellulose, calcium silicate, silica polyvinylpyrrolidone, cetostearyl alcohol, starch, gum acacia, calcium phosphate, cocoa butter, oil of theobroma, arachis oil, alginates, tragacanth, gelatin, methyl cellulose, polyoxyethylene sorbitan monolaurate, ethyl lactate, propylhydroxybenzoate, sorbitan trioleate, sorbitan sesquileate and oleyl alcohol.

[0171] Pharmaceutical compositions of the invention can be manufactured by methods well known in the art, including conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

[0172] For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as acetate, Hanks's solution, Ringer's solution, or physiological saline buffer. Preferably the solutions are sterile and non-pyrogenic. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0173] For oral administration, the active compound(s) can be combined with pharmaceutically acceptable carriers which enable the compound(s) to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. Fillers can be used, such as gelatin, sugars (e.g., lactose, sucrose, mannitol, or sorbitol); cellulose preparations (e.g., maize starch, wheat starch, rice starch, potato starch, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose); and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0174] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0175] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compound(s) may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration preferably are in dosages suitable for such administration.

[0176] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0177] For administration by inhalation, pharmaceutical preparations of the invention can be delivered in the form of an aerosol sprays from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. If desired, a valve can be used to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator, may be formulated containing a powder mix of a compound and a suitable powder base such as lactose or starch.

[0178] Compounds of the invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emul-

sions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0179] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0180] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0181] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0182] Compounds of the invention typically are soluble and stable in 50 mM acetate at a concentration of 10 mg/ml or above, and can be delivered intraperitoneally and orally in this buffer. Some compounds are soluble in hydroxypropyl- β -cyclodextrin (HBPCD, 3-5%), and can be delivered intraperitoneally and orally in this solvent. For intravenous delivery, compounds can be suspended or dissolved in 5% mannitol.

[0183] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0184] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0185] In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices including ALZET® osmotic pumps which are available from Alza Corporation. Suitable delivery devices are described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,944,064 and 4,008,719.

Therapeutic Methods

[0186] The identified compounds can be administered to a human patient, either alone or in pharmaceutical compositions where they are mixed with suitable carriers or excipient (s) at doses to treat or ameliorate blood-related cancers (e.g., lymphomas and leukemias) and autoimmune disorders. Reduction of intracellular kinase activity also is useful to suppress the immune system of transplant patients prior to, during, and/or after transplant.

[0187] Lymphomas are malignant growths of B or T cells in the lymphatic system, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. Non-Hodgkin's lymphomas include cutaneous T cell lymphomas (e.g., Sezary syndrome and Mycosis fungoides), diffuse large cell lymphoma, HTLV-1 associated T cell lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T cell lymphoma, central nervous system lymphoma, and AIDS-related lymphoma.

[0188] Leukemias include acute and chronic types of both lymphocytic and myelogenous leukemia (e.g. acute lymphocytic or lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T cell prolymphocytic leukemia, adult T cell leukemia, and hairy cell leukemia).

[0189] Autoimmune disorders include systemic lupus erythematosus, anti-phospholipid antibody syndrome, multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis, asthma, Hashimoto's thyroiditis, Reiter's syndrome, Sjögren's syndrome, Guillain-Barré syndrome, myasthenia gravis, large vessel vasculitis, medium vessel vasculitis, polyarteritis nodosa, pemphigus vulgaris, scleroderma, Goodpasture's syndrome, glomerulonephritis, primary biliary cirrhosis, Grave's disease, membranous nephropathy, autoimmune hepatitis, celiac sprue, Addison's disease, polymyositis, dermatomyositis, monoclonal gammopathy, Factor VIII deficiency, cryoglobulinemia, peripheral neuropathy, IgM polyneuropathy, chronic neuropathy, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, ankylosing spondylitis, vasculitis, inflammatory bowel disease, and type I diabetes mellitus. The autoimmune disease may involve a secretory cell, such as a T lymphocyte, B lymphocyte, Mast cell, or dendritic cell. Compounds of the invention also can be used to treat patients who undergo protein replacement therapies and who develop antibodies to the replacement.

[0190] Routes of Administration

[0191] Pharmaceutical preparations of the invention can be administered locally or systemically. Suitable routes of administration include oral, pulmonary, rectal, transmucosal, intestinal, parenteral (including intramuscular, subcutaneous, intramedullary routes), intranodal, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, transdermal, topical, and vaginal routes. As described in more detail above, dosage forms include, but are not limited to, tablets, troches, dispersions, suspensions, suppositories, solutions, capsules, creams, patches, minipumps and the like. Targeted delivery systems also can be used (for example, a liposome coated with target-specific antibody).

[0192] Dosage

[0193] A pharmaceutical composition of the invention comprises at least one active ingredient in a therapeutically effective amount. A "therapeutically effective dose" is the amount of an active agent which, when administered to a patient, results in a measurable improvement in a characteristic of the disease being treated (e.g., improved laboratory values, retarded development of a symptom, reduced severity of a symptom, improved levels of a biological marker such as CD25a or IL2). The improvement can be evident after a single administration of the therapeutically effective dose. More usually multiple administrations are utilized in order to achieve or maintain optimal effect. In preferred embodiments frequency of administration can range from twice a month to once a week to several times a day, for example 1-4 times a day. In alternative embodiments administration can be by

time-release formulations, or extended or continuous infusions. The frequency of administration can be selected to achieve a systemic or local concentration at or above some predetermined level for a period of time. The period of time can be all or a substantial portion of the interval between administrations or comprise the period of time-release or infusion. In some embodiments, the treatment schedule can require that a concentration of the compound be maintained for a period of time (e.g., several days or a week) and then allowed to decay by ceasing administration for a period of time (e.g., 1, 2, 3, or 4 weeks).

[0194] Determination of therapeutically effective amounts is well within the capability of those skilled in the art. A therapeutically effective dose initially can be estimated from in vitro enzyme assays, cell culture assays and/or animal models. For example, a dose can be formulated in an animal model to achieve a circulating concentration range that includes the IC₅₀ as determined in an in vitro enzyme assay or in a cell culture (i.e., the concentration of the test compound which achieves a half-maximal inhibition of ITK or BTK activity). Such information can be used to more accurately determine useful doses in humans.

[0195] Appropriate animal models for the relevant diseases are known in the art. See, e.g., *Exp Hematol.* 34, 284-88, 2006 (aggressive systemic mastocytosis and mast cell leukemia); *Leuk. Lymphoma.* 47, 521-29, 2006 (acute myeloid leukemia); *Leuk. Lymphoma.* 7, 79-86, 1992 (disseminated human B-lineage acute lymphoblastic leukemia and non-Hodgkins lymphoma); *J. Virol.* 79, 9449-57, 2006 (adult T-cell leukemia); *Neoplasia* 7, 984-91, 2005 (lymphoma); *Oligonucleotides* 15, 85-93, 005 (lymphoma); *Transfus. Apher. Sci.* 32, 197-203, 2005 (cutaneous T cell lymphoma); *Nature* 17, 254-56, 1991 (follicular lymphoma and diffuse large cell lymphoma); *Cell. Mol. Immunol.* 2, 461-65, 2005 (myasthenia gravis); *Proc. Natl. Acad. Sci. USA* 102, 11823-28, 2005 (type I diabetes); *Arthritis Rheum.* 50, 3250-59, 2004 (lupus erythematosus); *Clin. Exp. Immunol.* 99, 294-302, 1995 (Grave's disease); *J. Clin. Invest.* 116, 905-15, 2006 (multiple sclerosis); *Pharmacol Res.* e-published Feb. 1, 2006 (ulcerative colitis); *J. Pathol.* e-published Mar. 21, 2006 (Crohn's disease); *J. Clin. Invest.* 116, 961-973, 2006 (rheumatoid arthritis); *Endocrinol.* 147, 754-61, 2006 (asthma); *Exp Mol Pathol.* 77, 161-67, 2004 (Hashimoto's thyroiditis); *J. Rheumatol. Suppl.* 11, 114-17, 1983 (Reiter's syndrome); *Rheumatol.* 32, 1071-75, 2005 (Sjögren's syndrome); *Brain Pathol.* 12, 420-29, 2002 (Guillain-Barré syndrome); *J. Clin. Invest.* 110, 955-63, 2002 (vessel vasculitis); *Vet. Pathol.* 32, 337-45, 1995 (polyarteritis nodosa); *Immunol. Invest.* 3, 47-61, 2006 (pemphigus vulgaris); *Arch. Dermatol. Res.* 297, 333-44, 2006 (scleroderma); *J. Exp. Med.* 191, 899-906, 2000 (Goodpasture's syndrome); *J. Vet. Med. Sci.* 68, 65-68, 2006 (glomerulonephritis); *Liver Int.* 25, 595-603, 2005 (primary biliary cirrhosis); *Clin. Exp. Immunol.* 99, 294-302, 1995 (Grave's disease); *J. Clin. Invest.* 91, 1507-15, 1993 (membranous nephropathy); *J. Immunol.* 169, 4889-96, 2002 (autoimmune hepatitis); *Isr. J. Med. Sci.* 15, 348-55, 1979 (celiac sprue); *Surgery* 128, 999-1006, 2000 (Addison's disease); *J. Neuroimmunol.* 98, 130-35, 1999 (polymyositis); *Am. J. Pathol.* 120, 323-25, 1985 (dermatomyositis); *Bone* 20, 515-20, 1997 (monoclonal gammopathy); *Haemophilia* 11, 227-32, 2005 (Factor VIII deficiency); *Proc. Natl. Acad. Sci. USA* 94, 233-36, 1997 (cryoglobulinemia); *Pain* 110, 56-63, 2004 (peripheral neuropathy); *Ann. Neurol.* 49, 712-20, 2001 (IgM polyneuropathy); *J. Neurosci. Res.* 44, 58-65, 1996 (chronic

neuropathy); *Eur. J. Immunol.* 32, 1147-56, 2002 (autoimmune hemolytic anemia); *Haematologica* 88, 679-87, 2003 (autoimmune thrombocytopenic purpura); *Curr. Top. Microbiol. Immunol.* 293, 153-77, 2005 (pernicious anemia); *J. Immunol.* 175, 2475-83, 2005 (ankylosing spondylitis); *Inflamm. Res.* 53, 72-77, 2004 (vasculitis); *Vet. Pathol.* 43, 2-14, 2006 (inflammatory bowel disease); and *J. Biol. Chem.* 276, -13821, 2001 (anti-phospholipid antibody syndrome).

[0196] LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population) can be determined by standard pharmaceutical procedures in cell cultures and/or experimental animals. Data obtained from cell culture assays or animal studies can be used to determine initial human doses. As is known in the art, the dosage may vary depending upon the dosage form and route of administration used.


[0197] As is well known, the FDA guidance document "Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers" (HFA-305) provides an equation for use in calculating a human equivalent dose (HED) based on in vivo animal studies. Based on the studies described in Example 16, below, the human equivalent dose ranges between 1.5 mg/kg and 8 mg/kg, with some compounds showing considerable efficacy at lower or higher doses than those estimated by the HED. Thus, human dosages for systemic administration can range from, e.g., 1.5 mg/kg to 3 mg/kg; 2 mg/kg to 4 mg/kg; 5 mg/kg to 7 mg/kg; and 4 mg/kg to 8 mg/kg. The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the disorder, the manner of administration and the judgment of the prescribing physician.

[0198] All patents, patent applications, and references cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples, which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

Example 1

Preparation of 1-naphthalen-2-yl-prop-2-en-1-ol

[0199]




[0200] Naphthaldehyde (5.0 g, 32.0 mmole) was dissolved in anhydrous tetrahydrofuran and stirred at -78°C . under N₂ (g) atmosphere. To the mixture was added vinyl magnesium bromide (50 ml, 1 M solution in THF) and the reaction was warmed to room temperature and stirred overnight. The reaction was quenched with water and partitioned between EtOAc and water. The organic layer was washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give the desired product as yellow oil (5.0 g, 85%). ESI-MS m/z 185 (M+H)⁺.

Example 2

Preparation of 1-naphthalen-2-yl-propenone

[0201]




[0202] To a solution of 1-naphthalen-2-yl-prop-2-en-1-ol (1.3 g, 7.0 mmole) in 30 ml of dichloromethane was added pyridinium chlorochromate (1.5 g, 7.0 mmole). The mixture was stirred at room temperature until oxidation was complete. The solution was filtered through celite and the solvent was concentrated under vacuum. The residue was re-dissolved in EtOAc and washed with water and brine, dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by HPLC using a 0-100% EtOAc-Hx gradient to give the desired product as yellow oil (280 mg, 22%). ESI-MS m/z 183 (M+H)⁺.

Example 3

Preparation of 1-naphthalen-2-yl-3-piperidin-1-yl-propan-1-one

[0203]




[0204] 1-Naphthalen-2-yl-propenone (10 mg, 0.05 mmole) was dissolved in 100 μl of DMSO in one well of a 96 well polypropylene plate. To the mixture was added piperidine (12 μl , 0.10 mmole) and diisopropylethyl amine (17 μl , 0.1 mmole). After completion, the product was purified using HPLC to give the desired product (50 mm \times 10 mm Phenomenex GEMINITM column using a 30-100% acetonitrile-water gradient). ESI-MS m/z 268 (M+H)⁺.

Example 4

Preparation of 1H-Pyrrolo[2,3-b]pyridine 7-oxide

[0205]




[0206] 7-Azaindole (10 g, 84.7 mmol) was dissolved in ether (300 mL) at room temperature. M-CPBA (29.1 g, 1.5 eq.) was added in portions and stirred by manual agitation. After all oxidant was added, the mixture was stirred at room temperature for a further 3 hours. LC/MS showed complete conversion. The mixture was filtered, and the solid was washed with ether (40 mL x 3) and air-dried. NMR analysis of this solid in d₆-DMSO obtained showed the product as mostly the meta-Chloro benzoic acid salt of 1H-Pyrrolo[2,3-b]pyridine 7-oxide (off white, 17.9 g); MS: m/z 135.3 [MH⁺].

Example 5

Preparation of 4-Chloro-1H-pyrrolo[2,3-b]pyridine

[0207]




[0208] The m-CBA salt of 1H-Pyrrolo[2,3-b]pyridine 7-oxide (9 g) was taken into POCl₃ (46 mL, 7.5 eq.). The mixture was heated at 90° C. for 15 hours and to 106° C. for another 4 hours. The mixture was cooled to room temperature, and most of the POCl₃ was distilled off under high vacuum. The residue was dissolved in CH₃CN (10 mL). Water (20 mL) was added slowly to quench the reaction. The resulted mixture was adjusted to pH ~9 using 10 N NaOH. The solid was filtered. The crude solid was redissolved in several ml of THF and combiflashed using 0-10% MeOH in DCM to give 4-Chloro-1H-pyrrolo[2,3-b]pyridine as a slightly yellowish solid. (4 g). MS: m/z 154.9 [MH⁺].

Example 6

Preparation of 1-[4-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-phenyl]-ethanone

[0209]




[0210] 4-Chloro-1H-pyrrolo[2,3-b]pyridine (500 mg, 3.27 mmol) was dissolved in dioxane (11 mL). 4-Acetyl phenylboronic acid (802 mg, 4.9 mmol, 1.5 eq), dppfPdCl₂ (41 mg, 0.03 mmol, 0.01 eq) and Na₂CO₃ (2 N aq., 8.6 mL) were charged. The mixture was vacuumed and flushed with N₂ and microwaved at 160° C. for 15 minutes. Six batches of this same reaction were carried out. The crude mixture was pooled and partitioned between DCM (40 mL) and water (20

mL). Combi-flash of the residue using hexane/EtOAc (0% to 100%) gave the free base azaindole derivative as a slightly yellowish solid. The solid was redissolved in DCM (20 mL) and stirred in an ice bath. A 2M HCl solution in ether (10 mL) was added dropwise. The precipitate was filtered and dried to give 1-[4-(1H-Pyrrolo[2,3-b]pyridin-4-yl)-phenyl]-ethanone. (2.5 g, 48%). MS: m/z 237.3 [MH⁺].

Example 7

Preparation of 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone

[0211]





[0212] 2-Chloropyridine-4-boronic acid (11.0 g, 69.9 mmol), 3-Bromoacetophenone (11.2 mL, 83.9 mmol, 1.2 eq.), Na₂CO₃ (35 mL, 244.65 mmol, 3.5 eq.) and dppfPdCl₂ (572 mg, 0.07 mmol, 0.01 eq.) were mixed in THF (200 mL). The mixture was heated to reflux and continued at this temperature in vacuo for 6 hours. It was then cooled and concentrated in vacuo. The residue was partitioned between DCM and water (100 mL/40 mL). The layers were separated and the aqueous layer was washed further with DCM (2x40 mL). The combined organic layer was dried (Na₂SO₄) and filtered. The filtrate was concentrated, and the residue was chromatographed using 1/1 hexane/EtOAc to give 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone as a white solid (9.5 g, 58%). MS: m/z 232.1 [MH⁺].

Example 8

Preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide

[0213]






[0214] A degassed mixture of 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (500 mg, 2.16 mmol), benzamide (523 mg, 4.32 mmol, 2 eq.), Xantphos (120 mg, 0.21 mmol, 0.1 eq.), Pd(OAc)₂ (24 mg, 0.10 mmol, 0.05 eq.), K₂CO₃ (448 mg, 3.24 mmol, 1.5 eq.) in dioxane (12 mL) was irradiated with microwaves at 150° C. for 1 hour. LC/MS control. Conversion was mostly 100% based on disappearance of starting material. Dimer (M+: 392) being the major by-product. If any starting material is unreacted at this point, another portion of Xantphos and Pd(OAc)₂ may be added and the mixture microwaved for another 30 minutes. The mixture was then partitioned between DCM and water (20 mL/10 mL). The layers were separated and the aqueous layer was washed further with DCM (2×20 mL). The combined organic layer was dried (Na₂SO₄) and filtered. The filtrate was concentrated and the residue was chromatographed using 1/1 Hexane/EtOAc to give N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide as a white solid (375 mg, 55%). MS: m/z 317.1 [MH⁺].

Example 9

Preparation of N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide

[0215]




[0216] N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide (200 mg, 0.632 mmol), morpholine HCl salt (78 mg, 0.632 mmol, 1 eq.) and paraformaldehyde (19 mg, 0.632 mmol, 1 eq.) were mixed with dioxane (2 mL) in a microwave tube. It was irradiated at 180° C. for 15 minutes. The mixture was partitioned between DCM/water (10 mL/5 mL). The aqueous layer was washed further with DCM (2×10 mL). The combined organic layer was dried (Na₂SO₄) and filtered. The filtrate was concentrated and the residue was chromatographed using 20/1 DCM/MeOH to give N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide as a slightly yellow solid (100 mg, 38%). MS: m/z 416.3 [MH⁺].

Example 10

Preparation of 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one

[0217]




[0218] N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide (100 mg, 0.32 mmol) was dissolved in HCl (2 mL, 6 N). The mixture was irradiated with microwaves at 140° C. for 30 minutes. The mixture was diluted with DCM (20 mL) and neutralized with NaOH to pH ~9. The layers were separated and the aqueous layer was washed further with DCM (2×15 mL). The combined organic layer was dried (Na₂SO₄) and filtered. The filtrate was concentrated and the residue was purified to give 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one (TFA salt) as a white solid (84 mg, 78%). MS: m/z 312.3 [MH⁺].

Example 11

Preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide

[0219]




[0220] According the same procedure for the preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide, N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide (130 mg, 81%, slight impurity) was obtained from 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (100 mg, 0.43 mmol) and 4-tert-butylbenzamide (153 mg, 0.86 mmol). MS: m/z 373.1 [MH⁺].

Example 12

Preparation of 4-tert-Butyl-N-{4-[3-(3-morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide

[0221]




[0222] According to the same procedure for the preparation of 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one, 4-tert-Butyl-N-{4-[3-(3-morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-benzamide (12 mg, 30%) was obtained from N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-4-tert-butyl-benzamide (36 mg, 0.1 mmol). MS: m/z 472.3 [MH⁺].

Example 13

Preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-acetamide

[0223]




[0224] According the same procedure for the preparation of N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-benzamide, N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-acetamide (50 mg, 50%, slight impurity) was obtained from 1-[3-(2-Chloro-pyridin-4-yl)-phenyl]-ethanone (100 mg, 0.43 mmol) and acetamide (26 mg, 0.86 mmol). MS: m/z 255.1 [MH⁺].

Example 14

Preparation of N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-acetamide

[0225]



[0226] According to the same procedure for the preparation of 1-[3-(2-Amino-pyridin-4-yl)-phenyl]-3-morpholin-4-yl-propan-1-one, N-{4-[3-(3-Morpholin-4-yl-propionyl)-phenyl]-pyridin-2-yl}-acetamide (10 mg, 20%) was obtained from N-[4-(3-Acetyl-phenyl)-pyridin-2-yl]-acetamide (50 mg, 0.2 mmol). MS: m/z 354.3 [MH⁺].

Example 15

In Vitro Assays

[0227] Measurement of IL-2 Production

[0228] Human T cell lines were plated in 96 well plates pre-coated with anti-CD3 monoclonal antibodies. Wells were

either left untreated or treated with anti-CD28 for 2 days. The supernatant was collected and tested for IL-2 production in the presence or absence of a test compound using a human IL-2 ELISA assay.

[0229] T Cell Proliferation Assay

[0230] Human T cell lines were plated in 96 well plates pre-coated with anti-CD3 monoclonal antibodies. Wells were either left untreated or treated with anti-CD28 for 2 days. Cell proliferation was measured in the presence or absence of a test compound using a commercially available CELLTITER-GLO™ assay (Promega).

[0231] In Vitro Kinase Assays

[0232] Compounds were screened using the HITHUNTER™ enzyme fragment complementation method (Discoverx). Briefly, a recombinantly produced, N-terminally His-tagged ITK kinase domain (amino acids 352-617) was incubated with various concentrations of individual compounds. ATP and substrate were added, and the kinase reaction was allowed to proceed for 2-16 hours. Commercially available detection reagents were added and allowed to react for 2-4 hours. The reaction was evaluated by luminescence. Initial results were confirmed using full-length recombinant ITK protein.

[0233] Similarly, commercially available reagents such as HITHUNTER™ were used to evaluate the effect of compounds on the activity of additional kinases. The kinase domains of BTK, LCK and ERK were expressed as recombinant purified proteins were used for these studies.

[0234] The compounds in Table 1 were tested and shown to inhibit IL-2 production, to inhibit T cell proliferation, and to inhibit ITK with an IC₅₀ of less than 1 μM.

TABLE 1




Compound	IC ₅₀ (μM)
	0.01807
	0.00954
	0.01355

TABLE 1-continued







Compound	IC ₅₀ (μM)
	0.02851
	0.00533
	0.00426
	0.05043
	0.0114
	0.01327

TABLE 1-continued







Compound	IC ₅₀ (μM)
	0.00686
	0.02855
	0.01825

TABLE 1-continued

Compound	IC ₅₀ (μM)
	0.00085
	0.07194
	0.01964

[0235] The compounds in Tables 2-5 were tested in in vitro kinase assays:

TABLE 2




Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)	IC ₅₀ LCK (μM)
	0.005	0.42482	12.55299
	0.040	0.27584	2.89341
	0.04022	0.0369	8.03843

TABLE 2-continued










Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)	IC ₅₀ LCK (μM)
	0.013	1.41274	27.7419
	0.013	0.10223	34.05941
	0.014	1.83528	23.89837
	0.020		
	0.025	0.36501	NO IC ₅₀
	0.029	0.64341	413.06105
	0.035	0.94241	16.4214
	0.036	0.039	19.969
	0.043	0.6561	27.11277

TABLE 2-continued










Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)	IC ₅₀ LCK (μ M)
	0.056	0.86517	NO IC50
	0.065	1.24489	18.43928
	0.067	0.12463	28.09552
	0.072	0.7368	NO IC50
	0.065	0.39763	23.16665
	0.091	0.09415	18.46087
	0.077	0.77538	47.61179
	0.096	1.53948	20.8277
	0.104	0.23242	NO IC50

TABLE 2-continued










Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)	IC ₅₀ LCK (μM)
	0.148	0.77352	28.01341
	0.180	1.52018	163.63704
	0.186	3.67569	20.64831
	0.199	0.4735	NO IC50
	0.207	0.09415	18.46087
	0.208	2.89272	33.1157
	0.207	0.08071	NO IC50
	0.219	1.30729	NO IC50
	0.223	1.47599	21.15799

TABLE 2-continued










Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)	IC ₅₀ LCK (μ M)
	0.241	0.81405	NO IC50
	0.290	0.68214	25.86619
	0.305	0.74064	NO IC50
	0.345	3.1355	21.10834
	0.381	3.03351	32.57859
	0.385	1.47531	25.34326
	0.385	3.92321	23.25
	0.385	0.75252	23.94596
	0.468	1.21899	NO IC50

TABLE 2-continued









Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)	IC ₅₀ LCK (μ M)
	0.560	3.06627	24.36134
	0.569	1.01979	NO IC50
	0.611	2.31114	NO IC50
	0.797	3.62429	NO IC50
	0.935	0.99267	29.52378
	0.874	2.57662	NO IC50
	1.279	0.55617	704.77096
	1.406	4.1378	27.08267

TABLE 3















Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)	naphthyl analog	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)
	0.0059	0.7810		0.020	0.03947
	0.030	0.276		0.007	0.01276
	0.072	1.894		0.007	0.00215
	0.010	0.300		0.006	0.00338
	0.018	0.481		0.008	0.00152
	0.013	0.150		0.009	0.00654
	0.023	0.544		0.009	0.00072

TABLE 4








Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.05666	
	0.03034	
	0.09281	
	0.02285	
	0.07489	
	0.020	0.039
	0.048	5.001

TABLE 4-continued





Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.030	0.006
	3.339	2.364
	0.005	0.001
	0.042	0.002

TABLE 5




Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.0205	0.0395
	0.1369	8.21849
	0.0080	0.06706

TABLE 5-continued









Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.0169	
	0.0602	0.12799
	0.0148	
	0.5375	
	0.8516	
	0.0309	
	0.0212	
	0.1609	

TABLE 5-continued









Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.0242	
	0.0072	0.11532
	0.3096	
	0.0069	0.0492
	0.0187	
	0.0095	
	0.0162	
	0.0359	

TABLE 5-continued








Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.0147	
	0.0092	
	0.0062	0.16054
	0.0163	
	0.117	0.410
	0.023	0.153
	0.056	0.452

TABLE 5-continued








Compound	IC ₅₀ ITK (μ M)	IC ₅₀ BTK (μ M)
	0.060	0.242
	0.066	0.089
	0.064	0.360
	0.054	0.018
	0.087	0.051
	0.031	0.071
	0.066	0.117

TABLE 5-continued








Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)
	0.049	0.123
	0.086	0.084
	0.284	0.486
	0.217	0.266
	0.163	0.100
	0.036	0.004

TABLE 5-continued

Compound	IC ₅₀ ITK (μM)	IC ₅₀ BTK (μM)
	0.737	0.373

Example 16

In Vivo Studies

[0236] Several representative compounds were evaluated for efficacy in mouse in vivo tumor models. NOD/SCID mice were implanted intraperitoneally with T cell leukemia/lymphoma cells. One group was treated with vehicle alone (mock treatment) while the other groups were treated with several

small molecule inhibitors via intraperitoneal route. Tumor growth was evaluated by peritoneal lavage and FACS analysis. Table 6 summarizes percent inhibition of tumor growth relative to a mock group treated with vehicle alone. Doses of compounds evaluated in this study were below the maximal tolerated dose, and showed minimal toxicity.

[0237] The compounds in Table 6 were tested and inhibited tumor growth by at least 50% at the concentrations shown.

TABLE 6






Compound	mg/kg	% inhibition tumor growth
	100	70-90
	100	85-98
	80	92-99
	80	50-80
	80	90-99

TABLE 6-continued










Compound	mg/kg	% inhibition tumor growth
	80	99
	80	67-81
	80	92-99
	100	99
	80	97-99
	30	99
	100	99
	80	81-95

TABLE 6-continued

Compound	mg/kg	% inhibition tumor growth
	20	40
vehicle	—	0

Example 17

Compound Activity Mechanism

[0238] The compound class interacts selectively with kinase domains of such kinase families as Tec and EGFR, as well as a few additional kinases. There is evidence indicating that this class of compounds reacts irreversibly at the ATP binding site of the kinase binding domain, through a mechanism that involves the exposure of a reactive aminoethyl C=Y warhead through the in situ elimination of a leaving group. The compounds contain an abstractable proton adjacent to the C=Y group, which upon exposure to an appropriate catalytic environment in the active site of a kinase of interest will promote elimination of the beta-amino functionality. This elimination thus generates a reactive electrophilic species (commonly termed a Michael acceptor moiety) which, due to the existence of a proximal cysteine residue in the kinase active site, rapidly forms a covalent adduct between this cysteine residue and the in situ generated electrophilic species. The combination of a kinase with the catalytic environment in close proximity to a nucleophilic cysteine, is a vital and unique requirement that describes this mechanism of action. The data below support that in situ elimination promotes the inhibitory activity of compounds in depicted in this invention. When a compound is modified in a manner that prevents elimination, the compound fails to exhibit inhibitory activity.

TABLE 7




compound	IC ₅₀ ITK
	0.0446
	no IC ₅₀

TABLE 7-continued

compound	IC ₅₀ ITK
	no IC ₅₀

Example 18

Covalent Binding to Select Kinases

[0239] As a result of elimination in proximity of a relevant cysteine, a covalent adduct is formed between the compound and the kinase domain. The irreversible binding that ensues can be demonstrated by several methods, including surface plasmon resonance (SPR) and co-precipitation of the compound with the kinase.

[0240] BIACORE® is a SPR-based protein interaction approach, whereby the kinase is immobilized on the sensor chip, and a small molecule solution allowed to interact with the kinase. Detection of small molecule/kinase interaction occurs in real time, and is detected as a difference in SPR response. FIG. 1 shows a BIACORE® experiment in which the ITK kinase domain was immobilized on a biosensor, and evaluated for its ability to bind and dissociate from a small molecule. The data indicates that compounds depicted in this application bind to the ITK kinase domain irreversibly.




[0241] In the co-precipitation assay, 1-10 mM labeled compound is incubated with cell lysates from either kinase expressing or kinase lacking cells. The label is then used to precipitate the compound and any bound proteins. The mixture is separated by SDS-PAGE and proteins are identified by western blotting and/or Mass spectrophotometry.

Example 19

Contribution of Cysteine 442 to Adduct Formation

[0242] In order to confirm the mechanism by which compounds depicted herein interact with the kinase domain of Tec and EGFR kinases, we created a point mutant of the ITK kinase domain, whereby the key amino acid, namely C442 was mutated to alanine. The protein was expressed in a commercial baculovirus expression system using the manufacturer's general protocol (Invitrogen, pBlueBac). Protein was expressed and purified using standard techniques. Both wild type (WT) ITK kinase domain and C442A kinase domain exhibited kinase activity. While the activity of WT-ITK was inhibited by compounds depicted in this application, the same compounds had no activity towards the C442A mutant kinase domain.

TABLE 8

compound	IC ₅₀ (μM)	
	wild-type ITK	C442A-ITK
control (BMS-488516)	0.0392	0.0532
	0.011	>10
	0.0496	>10
	0.0111	>10

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 42

<210> SEQ ID NO 1

<211> LENGTH: 620

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

Met Asn Asn Phe Ile Leu Leu Glu Glu Gln Leu Ile Lys Lys Ser Gln
1 5 10 15

Gln Lys Arg Arg Thr Ser Pro Ser Asn Phe Lys Val Arg Phe Phe Val
20 25 30

Leu Thr Lys Ala Ser Leu Ala Tyr Phe Glu Asp Arg His Gly Lys Lys
35 40 45

Arg Thr Leu Lys Gly Ser Ile Glu Leu Ser Arg Ile Lys Cys Val Glu
50 55 60

Ile Val Lys Ser Asp Ile Ser Ile Pro Cys His Tyr Lys Tyr Pro Phe
65 70 75 80

Gln Val Val His Asp Asn Tyr Leu Leu Tyr Val Phe Ala Pro Asp Arg
85 90 95

Glu Ser Arg Gln Arg Trp Val Leu Ala Leu Lys Glu Glu Thr Arg Asn
100 105 110

Asn Asn Ser Leu Val Pro Lys Tyr His Pro Asn Phe Trp Met Asp Gly
115 120 125

Lys Trp Arg Cys Cys Ser Gln Leu Glu Lys Leu Ala Thr Gly Cys Ala

-continued

130		135		140											
Gln	Tyr	Asp	Pro	Thr	Lys	Asn	Ala	Ser	Lys	Lys	Pro	Leu	Pro	Pro	Thr
145					150					155					160
Pro	Glu	Asp	Asn	Arg	Arg	Pro	Leu	Trp	Glu	Pro	Glu	Glu	Thr	Val	Val
			165						170					175	
Ile	Ala	Leu	Tyr	Asp	Tyr	Gln	Thr	Asn	Asp	Pro	Gln	Glu	Leu	Ala	Leu
			180					185					190		
Arg	Arg	Asn	Glu	Glu	Tyr	Cys	Leu	Leu	Asp	Ser	Ser	Glu	Ile	His	Trp
		195					200					205			
Trp	Arg	Val	Gln	Asp	Arg	Asn	Gly	His	Glu	Gly	Tyr	Val	Pro	Ser	Ser
	210					215					220				
Tyr	Leu	Val	Glu	Lys	Ser	Pro	Asn	Asn	Leu	Glu	Thr	Tyr	Glu	Trp	Tyr
225					230					235					240
Asn	Lys	Ser	Ile	Ser	Arg	Asp	Lys	Ala	Glu	Lys	Leu	Leu	Leu	Asp	Thr
				245					250					255	
Gly	Lys	Glu	Gly	Ala	Phe	Met	Val	Arg	Asp	Ser	Arg	Thr	Ala	Gly	Thr
			260					265					270		
Tyr	Thr	Val	Ser	Val	Phe	Thr	Lys	Ala	Val	Val	Ser	Glu	Asn	Asn	Pro
		275					280					285			
Cys	Ile	Lys	His	Tyr	His	Ile	Lys	Glu	Thr	Asn	Asp	Asn	Pro	Lys	Arg
	290					295					300				
Tyr	Tyr	Val	Ala	Glu	Lys	Tyr	Val	Phe	Asp	Ser	Ile	Pro	Leu	Leu	Ile
305					310					315					320
Asn	Tyr	His	Gln	His	Asn	Gly	Gly	Gly	Leu	Val	Thr	Arg	Leu	Arg	Tyr
				325					330					335	
Pro	Val	Cys	Phe	Gly	Arg	Gln	Lys	Ala	Pro	Val	Thr	Ala	Gly	Leu	Arg
			340					345					350		
Tyr	Gly	Lys	Trp	Val	Ile	Asp	Pro	Ser	Glu	Leu	Thr	Phe	Val	Gln	Glu
		355					360					365			
Ile	Gly	Ser	Gly	Gln	Phe	Gly	Leu	Val	His	Leu	Gly	Tyr	Trp	Leu	Asn
	370					375					380				
Lys	Asp	Lys	Val	Ala	Ile	Lys	Thr	Ile	Arg	Glu	Gly	Ala	Met	Ser	Glu
385					390					395					400
Glu	Asp	Phe	Ile	Glu	Glu	Ala	Glu	Val	Met	Met	Lys	Leu	Ser	His	Pro
				405					410					415	
Lys	Leu	Val	Gln	Leu	Tyr	Gly	Val	Cys	Leu	Glu	Gln	Ala	Pro	Ile	Cys
			420					425					430		
Leu	Val	Phe	Glu	Phe	Met	Glu	His	Gly	Cys	Leu	Ser	Asp	Tyr	Leu	Arg
		435				440						445			
Thr	Gln	Arg	Gly	Leu	Phe	Ala	Ala	Glu	Thr	Leu	Leu	Gly	Met	Cys	Leu
	450					455						460			
Asp	Val	Cys	Glu	Gly	Met	Ala	Tyr	Leu	Glu	Glu	Ala	Cys	Val	Ile	His
465					470					475					480
Arg	Asp	Leu	Ala	Ala	Arg	Asn	Cys	Leu	Val	Gly	Glu	Asn	Gln	Val	Ile
				485					490					495	
Lys	Val	Ser	Asp	Phe	Gly	Met	Thr	Arg	Phe	Val	Leu	Asp	Asp	Gln	Tyr
			500					505					510		
Thr	Ser	Ser	Thr	Gly	Thr	Lys	Phe	Pro	Val	Lys	Trp	Ala	Ser	Pro	Glu
		515					520						525		
Val	Phe	Ser	Phe	Ser	Arg	Tyr	Ser	Ser	Lys	Ser	Asp	Val	Trp	Ser	Phe
	530					535					540				

-continued

Gly Val Leu Met Trp Glu Val Phe Ser Glu Gly Lys Ile Pro Tyr Glu
545 550 555 560

Asn Arg Ser Asn Ser Glu Val Val Glu Asp Ile Ser Thr Gly Phe Arg
565 570 575

Leu Tyr Lys Pro Arg Leu Ala Ser Thr His Val Tyr Gln Ile Met Asn
580 585 590

His Cys Trp Lys Glu Arg Pro Glu Asp Arg Pro Ala Phe Ser Arg Leu
595 600 605

Leu Arg Gln Leu Ala Glu Ile Ala Glu Ser Gly Leu
610 615 620

<210> SEQ ID NO 2
<211> LENGTH: 659
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Ala Ala Val Ile Leu Glu Ser Ile Phe Leu Lys Arg Ser Gln Gln
1 5 10 15

Lys Lys Lys Thr Ser Pro Leu Asn Phe Lys Lys Arg Leu Phe Leu Leu
20 25 30

Thr Val His Lys Leu Ser Tyr Tyr Glu Tyr Asp Phe Glu Arg Gly Arg
35 40 45

Arg Gly Ser Lys Lys Gly Ser Ile Asp Val Glu Lys Ile Thr Cys Val
50 55 60

Glu Thr Val Val Pro Glu Lys Asn Pro Pro Pro Glu Arg Gln Ile Pro
65 70 75 80

Arg Arg Gly Glu Glu Ser Ser Glu Met Glu Gln Ile Ser Ile Ile Glu
85 90 95

Arg Phe Pro Tyr Pro Phe Gln Val Val Tyr Asp Glu Gly Pro Leu Tyr
100 105 110

Val Phe Ser Pro Thr Glu Glu Leu Arg Lys Arg Trp Ile His Gln Leu
115 120 125

Lys Asn Val Ile Arg Tyr Asn Ser Asp Leu Val Gln Lys Tyr His Pro
130 135 140

Cys Phe Trp Ile Asp Gly Gln Tyr Leu Cys Cys Ser Gln Thr Ala Lys
145 150 155 160

Asn Ala Met Gly Cys Gln Ile Leu Glu Asn Arg Asn Gly Ser Leu Lys
165 170 175

Pro Gly Ser Ser His Arg Lys Thr Lys Lys Pro Leu Pro Pro Thr Pro
180 185 190

Glu Glu Asp Gln Ile Leu Lys Lys Pro Leu Pro Pro Glu Pro Ala Ala
195 200 205

Ala Pro Val Ser Thr Ser Glu Leu Lys Lys Val Val Ala Leu Tyr Asp
210 215 220

Tyr Met Pro Met Asn Ala Asn Asp Leu Gln Leu Arg Lys Gly Asp Glu
225 230 235 240

Tyr Phe Ile Leu Glu Glu Ser Asn Leu Pro Trp Trp Arg Ala Arg Asp
245 250 255

Lys Asn Gly Gln Glu Gly Tyr Ile Pro Ser Asn Tyr Val Thr Glu Ala
260 265 270

Glu Asp Ser Ile Glu Met Tyr Glu Trp Tyr Ser Lys His Met Thr Arg

-continued

275					280					285					
Ser	Gln	Ala	Glu	Gln	Leu	Leu	Lys	Gln	Glu	Gly	Lys	Glu	Gly	Gly	Phe
290						295					300				
Ile	Val	Arg	Asp	Ser	Ser	Lys	Ala	Gly	Lys	Tyr	Thr	Val	Ser	Val	Phe
305					310					315					320
Ala	Lys	Ser	Thr	Gly	Asp	Pro	Gln	Gly	Val	Ile	Arg	His	Tyr	Val	Val
				325					330					335	
Cys	Ser	Thr	Pro	Gln	Ser	Gln	Tyr	Tyr	Leu	Ala	Glu	Lys	His	Leu	Phe
			340					345					350		
Ser	Thr	Ile	Pro	Glu	Leu	Ile	Asn	Tyr	His	Gln	His	Asn	Ser	Ala	Gly
		355					360					365			
Leu	Ile	Ser	Arg	Leu	Lys	Tyr	Pro	Val	Ser	Gln	Gln	Asn	Lys	Asn	Ala
	370					375					380				
Pro	Ser	Thr	Ala	Gly	Leu	Gly	Tyr	Gly	Ser	Trp	Glu	Ile	Asp	Pro	Lys
385					390					395					400
Asp	Leu	Thr	Phe	Leu	Lys	Glu	Leu	Gly	Thr	Gly	Gln	Phe	Gly	Val	Val
				405					410					415	
Lys	Tyr	Gly	Lys	Trp	Arg	Gly	Gln	Tyr	Asp	Val	Ala	Ile	Lys	Met	Ile
			420					425					430		
Lys	Glu	Gly	Ser	Met	Ser	Glu	Asp	Glu	Phe	Ile	Glu	Glu	Ala	Lys	Val
		435					440					445			
Met	Met	Asn	Leu	Ser	His	Glu	Lys	Leu	Val	Gln	Leu	Tyr	Gly	Val	Cys
	450					455					460				
Thr	Lys	Gln	Arg	Pro	Ile	Phe	Ile	Ile	Thr	Glu	Tyr	Met	Ala	Asn	Gly
465					470					475					480
Cys	Leu	Leu	Asn	Tyr	Leu	Arg	Glu	Met	Arg	His	Arg	Phe	Gln	Thr	Gln
				485					490					495	
Gln	Leu	Leu	Glu	Met	Cys	Lys	Asp	Val	Cys	Glu	Ala	Met	Glu	Tyr	Leu
			500					505					510		
Glu	Ser	Lys	Gln	Phe	Leu	His	Arg	Asp	Leu	Ala	Ala	Arg	Asn	Cys	Leu
		515					520					525			
Val	Asn	Asp	Gln	Gly	Val	Val	Lys	Val	Ser	Asp	Phe	Gly	Leu	Ser	Arg
	530					535					540				
Tyr	Val	Leu	Asp	Asp	Glu	Tyr	Thr	Ser	Ser	Val	Gly	Ser	Lys	Phe	Pro
545					550					555					560
Val	Arg	Trp	Ser	Pro	Pro	Glu	Val	Leu	Met	Tyr	Ser	Lys	Phe	Ser	Ser
				565					570					575	
Lys	Ser	Asp	Ile	Trp	Ala	Phe	Gly	Val	Leu	Met	Trp	Glu	Ile	Tyr	Ser
			580					585					590		
Leu	Gly	Lys	Met	Pro	Tyr	Glu	Arg	Phe	Thr	Asn	Ser	Glu	Thr	Ala	Glu
		595					600					605			
His	Ile	Ala	Gln	Gly	Leu	Arg	Leu	Tyr	Arg	Pro	His	Leu	Ala	Ser	Glu
	610					615					620				
Lys	Val	Tyr	Thr	Ile	Met	Tyr	Ser	Cys	Trp	His	Glu	Lys	Ala	Asp	Glu
625					630					635					640
Arg	Pro	Thr	Phe	Lys	Ile	Leu	Leu	Ser	Asn	Ile	Leu	Asp	Val	Met	Asp
				645					650					655	
Glu	Glu	Ser													

<210> SEQ ID NO 3

<211> LENGTH: 35

-continued

```

<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Leu Thr Phe Leu Lys Glu Leu Gly Thr Gly Gln Phe Gly Val Val Lys
1           5           10           15

Tyr Gly Lys Trp Arg Gly Gln Tyr Asp Val Ala Ile Lys Met Ile Lys
           20           25           30

Glu Gly Ser
           35

<210> SEQ ID NO 4
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Ile Thr Leu Leu Lys Glu Leu Gly Ser Gly Gln Phe Gly Val Val Gln
1           5           10           15

Leu Gly Lys Trp Lys Gly Gln Tyr Asp Val Ala Val Lys Met Ile Lys
           20           25           30

Glu Gly Ser
           35

<210> SEQ ID NO 5
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Leu Thr Phe Met Arg Glu Leu Gly Ser Gly Leu Phe Gly Val Val Arg
1           5           10           15

Leu Gly Lys Trp Arg Ala Gln Tyr Lys Val Ala Ile Lys Ala Ile Arg
           20           25           30

Glu Gly Ala
           35

<210> SEQ ID NO 6
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Leu Ala Phe Ile Lys Glu Ile Gly Ser Gly Gln Phe Gly Val Val His
1           5           10           15

Leu Gly Glu Trp Arg Ser His Ile Gln Val Ala Ile Lys Ala Ile Asn
           20           25           30

Glu Gly Ser
           35

<210> SEQ ID NO 7
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Leu Thr Phe Val Gln Glu Ile Gly Ser Gly Gln Phe Gly Leu Val His
1           5           10           15

```

-continued

Leu Gly Tyr Trp Leu Asn Lys Asp Lys Val Ala Ile Lys Thr Ile Arg
 20 25 30

Glu Gly Ala
 35

<210> SEQ ID NO 8
 <211> LENGTH: 35
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Leu Arg Leu Val Arg Lys Leu Gly Ser Gly Gln Phe Gly Glu Val Trp
 1 5 10 15

Met Gly Tyr Tyr Lys Asn Asn Met Lys Val Ala Ile Lys Thr Leu Lys
 20 25 30

Glu Gly Thr
 35

<210> SEQ ID NO 9
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Phe Lys Lys Ile Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr
 1 5 10 15

Lys Gly Leu Trp Ile Pro Glu Gly Glu Lys Val Lys Ile Pro Val Ala
 20 25 30

Ile Lys Glu Leu Arg Glu Ala Thr
 35 40

<210> SEQ ID NO 10
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

Leu Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr
 1 5 10 15

Lys Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala
 20 25 30

Ile Lys Val Leu Arg Glu Asn Thr
 35 40

<210> SEQ ID NO 11
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Leu Lys Arg Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr
 1 5 10 15

Lys Gly Ile Trp Val Pro Glu Gly Glu Thr Val Lys Ile Pro Val Ala
 20 25 30

Ile Lys Ile Leu Asn Glu Thr Thr
 35 40

<210> SEQ ID NO 12

-continued

<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12
Leu Lys Tyr Ile Ser Gln Leu Gly Lys Gly Asn Phe Gly Ser Val Glu
1 5 10 15
Leu Cys Arg Tyr Asp Pro Leu Ala His Asn Thr Gly Ala Leu Val Ala
20 25 30
Val Lys Gln Leu Gln His Ser Gly
35 40

<210> SEQ ID NO 13
<211> LENGTH: 36
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13
Met Ser Glu Asp Glu Phe Ile Glu Glu Ala Lys Val Met Met Asn Leu
1 5 10 15
Ser His Glu Lys Leu Val Gln Leu Tyr Gly Val Cys Thr Lys Gln Arg
20 25 30
Pro Ile Phe Ile
35

<210> SEQ ID NO 14
<211> LENGTH: 36
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14
Met Ser Glu Asp Glu Phe Phe Gln Glu Ala Gln Thr Met Met Lys Leu
1 5 10 15
Ser His Pro Lys Leu Val Lys Phe Tyr Gly Val Cys Ser Lys Glu Tyr
20 25 30
Pro Ile Tyr Ile
35

<210> SEQ ID NO 15
<211> LENGTH: 36
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15
Met Cys Glu Glu Asp Phe Ile Glu Glu Ala Lys Val Met Met Lys Leu
1 5 10 15
Thr His Pro Lys Leu Val Gln Leu Tyr Gly Val Cys Thr Gln Gln Lys
20 25 30
Pro Ile Tyr Ile
35

<210> SEQ ID NO 16
<211> LENGTH: 36
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16
Met Ser Glu Glu Asp Phe Ile Glu Glu Ala Lys Val Met Met Lys Leu
1 5 10 15

-continued

Ser His Ser Lys Leu Val Gln Leu Tyr Gly Val Cys Ile Gln Arg Lys
 20 25 30

Pro Leu Tyr Ile
 35

<210> SEQ ID NO 17
 <211> LENGTH: 36
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Met Ser Glu Glu Asp Phe Ile Glu Glu Ala Glu Val Met Met Lys Leu
 1 5 10 15

Ser His Pro Lys Leu Val Gln Leu Tyr Gly Val Cys Leu Glu Gln Ala
 20 25 30

Pro Ile Cys Leu
 35

<210> SEQ ID NO 18
 <211> LENGTH: 35
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

Met Ser Pro Glu Ala Phe Leu Gly Glu Ala Asn Val Met Lys Ala Leu
 1 5 10 15

Gln His Glu Arg Leu Val Arg Leu Tyr Ala Val Val Thr Lys Glu Pro
 20 25 30

Ile Tyr Ile
 35

<210> SEQ ID NO 19
 <211> LENGTH: 37
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala
 1 5 10 15

Ser Val Asp Asn Pro His Val Cys Arg Leu Leu Gly Ile Cys Leu Thr
 20 25 30

Ser Thr Val Gln Leu
 35

<210> SEQ ID NO 20
 <211> LENGTH: 37
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20

Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp Glu Ala Tyr Val Met Ala
 1 5 10 15

Gly Val Gly Ser Pro Tyr Val Ser Arg Leu Leu Gly Ile Cys Leu Thr
 20 25 30

Ser Thr Val Gln Leu
 35

-continued

```

<210> SEQ ID NO 21
<211> LENGTH: 37
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

Gly Pro Lys Ala Asn Val Glu Phe Met Asp Glu Ala Leu Ile Met Ala
1           5           10           15

Ser Met Asp His Pro His Leu Val Arg Leu Leu Gly Val Cys Leu Ser
           20           25           30

Pro Thr Ile Gln Leu
           35

```

```

<210> SEQ ID NO 22
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22

Pro Asp Gln Gln Arg Asp Phe Gln Arg Glu Ile Gln Ile Leu Lys Ala
1           5           10           15

Leu His Ser Asp Phe Ile Val Lys Tyr Arg Gly Val Ser Tyr Gly Pro
           20           25           30

Gly Arg Pro Glu Leu Arg Leu
           35

```

```

<210> SEQ ID NO 23
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 23

Ile Thr Glu Tyr Met Ala Asn Gly Cys Leu Leu Asn Tyr Leu Arg Glu
1           5           10           15

Met Arg His Arg Phe Gln Thr Gln Gln Leu Leu Glu Met Cys Lys Asp
           20           25           30

Val

```

```

<210> SEQ ID NO 24
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

Val Thr Glu Tyr Ile Ser Asn Gly Cys Leu Leu Asn Tyr Leu Arg Ser
1           5           10           15

His Gly Lys Gly Leu Glu Pro Ser Gln Leu Leu Glu Met Cys Tyr Asp
           20           25           30

Val

```

```

<210> SEQ ID NO 25
<211> LENGTH: 33
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

Val Thr Glu Phe Met Glu Arg Gly Cys Leu Leu Asn Phe Leu Arg Gln
1           5           10           15

```

-continued

Arg Gln Gly His Phe Ser Arg Asp Val Leu Leu Ser Met Cys Gln Asp
 20 25 30

Val

<210> SEQ ID NO 26
 <211> LENGTH: 33
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26

Val Thr Glu Phe Met Glu Asn Gly Cys Leu Leu Asn Tyr Leu Arg Glu
 1 5 10 15

Asn Lys Gly Lys Leu Arg Lys Glu Met Leu Leu Ser Val Cys Gln Asp
 20 25 30

Ile

<210> SEQ ID NO 27
 <211> LENGTH: 33
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

Val Phe Glu Phe Met Glu His Gly Cys Leu Ser Asp Tyr Leu Arg Thr
 1 5 10 15

Gln Arg Gly Leu Phe Ala Ala Glu Thr Leu Leu Gly Met Cys Leu Asp
 20 25 30

Val

<210> SEQ ID NO 28
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

Val Thr Glu Tyr Met Ala Arg Gly Cys Leu Leu Asp Phe Leu Lys Thr
 1 5 10 15

Asp Glu Gly Ser Arg Leu Ser Leu Pro Arg Leu Ile Asp Met Ser Ala
 20 25 30

Gln Ile Ala Glu Gly Met Ala Tyr
 35 40

<210> SEQ ID NO 29
 <211> LENGTH: 39
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

Ile Thr Gln Leu Met Pro Phe Gly Cys Leu Leu Asp Tyr Val Arg Glu
 1 5 10 15

His Lys Asp Asn Ile Gly Ser Gln Tyr Leu Leu Asn Trp Cys Val Gln
 20 25 30

Ile Ala Lys Gly Met Asn Tyr
 35

<210> SEQ ID NO 30
 <211> LENGTH: 39
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 30

Val Thr Gln Leu Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu
 1 5 10 15

Asn Arg Gly Arg Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln
 20 25 30

Ile Ala Lys Gly Met Ser Tyr
 35

<210> SEQ ID NO 31

<211> LENGTH: 39

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 31

Val Thr Gln Leu Met Pro His Gly Cys Leu Leu Glu Tyr Val His Glu
 1 5 10 15

His Lys Asp Asn Ile Gly Ser Gln Leu Leu Leu Asn Trp Cys Val Gln
 20 25 30

Ile Ala Lys Gly Met Met Tyr
 35

<210> SEQ ID NO 32

<211> LENGTH: 39

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

Val Met Glu Tyr Leu Pro Ser Gly Cys Leu Arg Asp Phe Leu Gln Arg
 1 5 10 15

His Arg Ala Arg Leu Asp Ala Ser Arg Leu Leu Leu Tyr Ser Ser Gln
 20 25 30

Ile Cys Lys Gly Met Glu Tyr
 35

<210> SEQ ID NO 33

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 33

Phe Leu His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Asn Asp Gln
 1 5 10 15

Gly Val Val Lys Val Ser Asp Phe Gly Leu Ser Arg Tyr Val Leu Asp
 20 25 30

Asp Glu Tyr
 35

<210> SEQ ID NO 34

<211> LENGTH: 35

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Asp Arg Asp
 1 5 10 15

Leu Cys Val Lys Val Ser Asp Phe Gly Met Thr Arg Tyr Val Leu Asp
 20 25 30

-continued

Asp Gln Tyr
35

<210> SEQ ID NO 35
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Glu Ala
1 5 10 15

Gly Val Val Lys Val Ser Asp Phe Gly Met Ala Arg Tyr Phe Leu Asp
20 25 30

Asp Gln Tyr
35

<210> SEQ ID NO 36
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Tyr Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Ser Ser Thr
1 5 10 15

Cys Ile Val Lys Ile Ser Asp Phe Gly Met Thr Arg Tyr Val Leu Asp
20 25 30

Asp Glu Tyr
35

<210> SEQ ID NO 37
<211> LENGTH: 35
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 37

Val Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Gly Glu Asn
1 5 10 15

Gln Val Ile Lys Val Ser Asp Phe Gly Met Thr Arg Phe Val Leu Asp
20 25 30

Asp Gln Tyr
35

<210> SEQ ID NO 38
<211> LENGTH: 39
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 38

Ile Glu Arg Met Asn Ser Ile His Arg Asp Leu Arg Ala Ala Asn Ile
1 5 10 15

Leu Val Ser Glu Ala Leu Cys Cys Lys Ile Ala Asp Phe Gly Leu Ala
20 25 30

Arg Ile Ile Asp Ser Glu Tyr
35

<210> SEQ ID NO 39
<211> LENGTH: 40
<212> TYPE: PRT

-continued

```

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 39

Leu Glu Asp Arg Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val
1           5           10           15

Leu Val Lys Thr Pro Gln His Val Lys Ile Thr Asp Phe Gly Leu Ala
           20           25           30

Lys Leu Leu Gly Ala Glu Glu Lys
           35           40

<210> SEQ ID NO 40
<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val
1           5           10           15

Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe Gly Leu Ala
           20           25           30

Arg Leu Leu Asp Ile Asp Glu Thr
           35           40

<210> SEQ ID NO 41
<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 41

Leu Glu Glu Arg Arg Leu Val His Arg Asp Leu Ala Ala Arg Asn Val
1           5           10           15

Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe Gly Leu Ala
           20           25           30

Arg Leu Leu Glu Gly Asp Glu Lys
           35           40

<210> SEQ ID NO 42
<211> LENGTH: 40
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42

Leu Gly Ser Arg Arg Cys Val His Arg Asp Leu Ala Ala Arg Asn Ile
1           5           10           15

Leu Val Glu Ser Glu Ala His Val Lys Ile Ala Asp Phe Gly Leu Ala
           20           25           30

Lys Leu Leu Pro Leu Asp Lys Asp
           35           40

```

1. A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of an interleukin-2 inducible tyrosine kinase (ITK) inhibitor.

2. The method of claim 1 wherein the cancer is a blood cell malignancy.

3. The method of claim 2 wherein the blood cell malignancy is a lymphoma.

4. The method of claim 3 wherein the lymphoma is Hodgkin's lymphoma.

5. The method of claim 3 wherein the lymphoma is non-Hodgkin's lymphoma.

6. The method of claim 5 wherein the non-Hodgkin's lymphoma is selected from the group consisting of cutaneous T cell lymphoma, diffuse large cell lymphoma, HTLV-1 associated T lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T lymphoma, central nervous system lymphoma, cutaneous T cell lymphoma (CTCL), and AIDS-related lymphoma.

7. The method of claim 2 wherein the blood cell malignancy is a leukemia.

8. The method of claim 7 wherein the leukemia is selected from the group consisting of acute lymphocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T prolymphocytic leukemia, adult T cell leukemia (ATL), and hairy cell leukemia.

9. The method of claim 2 wherein the blood cell malignancy is a mast cell malignancy.

10. The method of claim 5 wherein the non-Hodgkin's lymphoma is CTCL, and the CTCL is mycosis fungoides.

11. The method of claim 5 wherein the non-Hodgkin's lymphoma is CTCL, and the CTCL is Sezary syndrome.

12. The method of claim 1 wherein cells of the cancer express ITK.

13. The method of claim 1 wherein cells of the cancer express Bruton's tyrosine kinase (BTK).

* * * * *